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ABSTRACT 
 
 Ribonucleotide reductase (RNR) is an enzyme that catalyzes the conversion of 
ribonucleotides to C2ʹ-deoxyribonucleotides, the building blocks for both DNA 
synthesis and repair in all living organisms, via controlled radical chemistry. Since 
RNR expression is elevated in many cancers, this enzyme is a major target of 
anticancer drugs. Until recently, the only clinically proven RNR-inhibition pathway 
was a suicide inactivation in which synthetic substrate analogues, for instance, 
gemcitabine diphosphate (F2CDP), irreversibly inactivate the RNR-α2β2 heterodimeric 
complex. Recently, Clofarabine (ClF) nucleotides have been shown to reversibly 
inhibit the enzyme by targeting the large subunit of RNR (RNR-α) and inducing RNR-
α-persistent hexamerization. To date, ClF nucleotides are the only known examples of 
this mechanism. In order to establish whether this reversible inhibition is a common 
mode of inhibition among nucleotide-derivative drugs, the active forms of two other 
drugs, Cladribine (ClA) and Fludarabine (FlU), were chemoenzymatically synthesized 
and their mechanism(s) of inhibition of RNR were evaluated. Enzyme inhibition and 
fluorescence anisotropy assays show that di- and triphosphates of these two 
nucleosides reversibly inhibit RNR with diverse Ki values, fairly dispersed in a range 
of 0.5–10 µM, and bind to the catalytic site (C-site) and the allosteric activity site (A-
site) of RNR-α, respectively. Our EM studies, gel filtration, FRET, and protease 
digestion assays suggest that RNR-inhibition is coupled with the formation of 
 conformationally distinct hexamers. Studies in Flp-In HEK293 T-REx cells capable of 
selectively inducing either wild-type or oligomerization-defective mutant RNR-α 
overexpression define the central role of RNR-α oligomerization in drug activity, and 
highlight a potential resistant mechanism to these drugs. The results of these studies 
set the stage for new interventions targeting RNR oligomeric regulation.  
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 CHAPTER 1 
 
Ribonucleotide Reductases 
 
1.1 General overview  
 
 Ribonucleotide reductases (RNRs) are enzymes responsible for the reduction 
of ribonucleotides to C2ʹ-deoxyribonucleotides, the building blocks for both DNA 
synthesis and repair in all living organisms (Figure 1-1).1-4 Since either elevated or 
unbalanced levels of the four deoxynucleoside triphosphates (dNTPs) increase the 
mutation rate dramatically, cell thus must have a tight control over the synthesis of 
these DNA precursors.5  
 
 
 
 
 
 
 
NDPs, Nucleoside Diphosphates; NTPs, Nucleoside Triphosphates. 
 
 
Figure 1-1. Class I and some class II RNRs catalyze the reduction of NDPs, whereas 
class III and other class II RNRs operate at the NTPs level.5,6 However, all RNRs 
provide precursors for DNA synthesis and repair.  
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 As RNR plays a central role in this de novo synthesis, Nature invented 
sophisticated mechanisms, e.g., gene transcription, protein degradation, mRNA 
stability, specific inhibitors as well as a unique allosteric control, to regulate the 
enzyme activity on many levels.1,5 Under a scope of this study, we will only focus on 
enzyme allosteric regulation.  
 In nearly all cellular organisms and many viruses, RNRs initiate the reduction 
process of nucleotides by utilizing an essential thiyl radical, which is adjacent to the 
substrate at the active site, to subtract a 3ʹ-hydrogen from the substrate (more detail 
about RNR catalysis is discussed below, Figure 1-4).1,7,8 RNRs have been classified 
into three major classes and a few subclasses (Table 1-1, Figure 1-2)9 largely based on 
how this radical can be (re)generated in each catalysis cycle.1,5,10,11 Class I RNRs have 
a tyrosyl radical that is generated and stabilized by an oxo-bridged binuclear complex 
located in another subunit (β). Since oxygen is required for the metal center formation, 
class I RNRs sometimes are called the aerobic RNRs. Class II RNRs utilize 
adenosylcobalamin to generate a deoxyadenosyl radical under both aerobic and 
anaerobic conditions.4,6,12 Class III RNRs only function in anaerobic surroundings and 
require an oxygen-sensitive glycyl radical5 generated by a process that involves [Fe–S] 
cluster and S-adenosyl methionine.12 While the radical from either class II 
deoxyadenosyl radical or class III glycyl radical comes into direct contact with the 
active site cysteine in catalytic subunit (α)5,13, the radical from class I tyrosyl radical 
needs to be transferred from the β subunit to the active site cysteine residue via the 
putative proton-coupled electron transfer (PCET) pathway. Other differences among 
RNRs, e.g., oxygen dependency, subunit composition and allosteric regulation, are 
also used as criteria to classified RNRs (Table 1-1).5  
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Table 1-1. Three major classes of RNRs classified by their free radical chemistry, 
oxygen dependence, subunit composition, and allosteric regulation. Class I is further 
divided into three subclasses based on the identity of the metallocofactor.1,5,10,11  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 §In 2014, Wei et al discovered a new subtype of class III RNRs in Neisseria bacilliformis. Unlike class 
III RNRs studied to date that utilize formate as a reductant, this subclass facilitates the nucleotide 
reduction using the ubiquitous thioredoxin/thioredoxin reductase/NADPH system.14   
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α, the catalytic subunit where the NDPs reduction occurs; β, the smaller subunit, assembles the 
metallocofactors in class I and class III. 
 
Figure 1-2. Models of the three different classes of RNRs, taken from Ref. 9. Space-
filling models represent substrates and allosteric effectors. A) The active α2β2 
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holocomplex in class Ia. This model was made based on the crystal structures of E. 
coli RNR-α (PDB: 1RLR)8 and E. coli RNR-β (PBD: 1RIB)15 subunits. An N-terminal 
ATP cone is where ATP/dATP binds to the enzyme and regulates its activity. B) The 
monomeric class II from L. leichmannii (PDB: 1L1L).16 There is a small structural 
extension in this monomeric class II enzyme substituting the specificity effector-
binding site that, in the case of dimeric state, is constituted by another monomeric 
RNR-α.1 C) The dimeric class II from T. maritima (PDB: 3O0O).17 Stick models (in 
B–C) represent the adenosylcobalamin cofactors in the class II enzymes. D) 
Bacteriophage T4 Class III (PDB: 1HK8).18 Inset shows a homology model of a β-
monomer for this class.  
 
 Intriguingly, it is known that one organism can have multiple classes of RNRs, 
though, the expression of which depends on growth conditions.11 For example, E. coli 
possesses three classes of RNRs (class Ia, Ib and III), where class Ia is expressed 
under typical conditions. Since E. coli class Ib RNR is not essential for E. coli growth, 
it is poorly expressed.19,20 However, when the surrounding environment changes to 
microaerophilic or anaerobic conditions, E. coli class III RNR is instead expressed.19 
In this thesis, we will mainly focus on class Ia RNRs. 
 Class I RNRs are found almost in all eukaryotes and some eubacteria, viruses 
and bacteriophages.3,21 They contain two dissimilar subunits, α and β, which both 
function as homodimers (α2 and β2) and are needed for enzyme activity. In all 
eukaryotes, interactions between α2 and β2 can lead to the formation of an αnβm 
complex, of which minimally active form is the α2β2 heterodimeric complex.21-25  
 During the enzyme catalysis of class Ia RNRs, their stable tyrosyl radical 
required for enzymatic turnover is generated in the β subunit by the FeIII–O–FeIII 
center and subsequently transferred to the α subunit via the PCET pathway, generating 
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the active thiyl radical at the catalytic site (C-site) (Figure 1-3).1,5,8 More detail of how 
this thiyl radical is generated and transferred to the active site cysteine is later 
discussed in section 1.3. In addition to the C-site, this larger subunit contains two 
allosteric sites, the allosteric activity site (A-site) and the specificity site (S-site). In the 
absence of nucleotides, the α subunit is present as a monomer.21,22,25-29 However, upon 
binding of triphosphate effectors to the S-site, α dimerization is induced, which 
consequently primes α for substrate selection at the C-site. Binding of ATP (the 
positive activity effector) or dATP (the negative activity effector) to the A-site, on the 
other hand, controls the enzyme overall activity (Figure 1-3).1,5,22  
 
 
 
 
 
 
 
PCET, Proton-Coupled Electron Transfer. 
 
Figure 1-3. The active α2β2 holocomplex of class Ia RNRs. The radical from the 
transient tyrosyl radical in the β subunit is transferred to the catalytic site (C-site) 
cysteine residue in the α subunit via PCET pathway, initiating radical-based chemistry 
on the NDP substrates. Binding of effectors to the allosteric activity site (A-site) and 
the specificity site (S-site) controls the overall enzyme activity and which substrates 
are reduced at the C-site, respectively.1,5  
 
 The generic mechanism of NDPs reduction catalyzed by E. coli class Ia RNRs 
with its natural substrate is quite well established to date (Figure 1-4A).6,14,24,30-32 The 
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substrate reduction is initiated by the abstraction of the C3ʹ hydrogen atom by a 
transient, conserved, top face thiyl radical33 in the C-site, generating a substrate radical 
intermediate 2.34-36 A loss of water molecule from the C2ʹ position in the next step, 
which leads to the formation of a ketyl radical in state 3, likely involves general base 
catalysis by a conserved glutamate. This radical can be subsequently reduced by the 
bottom face conserved cysteines32, generating a C3ʹ-keto nucleotide and a disulfide 
anion radical37 (state 4). This anion radical then serves as the reductant for the 
substrate C3ʹ-keto nucleotide, forming a C3ʹ-deoxynucleotide radical and a disulfide 
bridge (state 5). Regeneration of the top face thiyl radical finally leads to product 
formation.14 The radical in this final state 6 is then transferred via the PCET pathway 
back to the β subunit, reforming the stable tyrosyl radical. However, for the complete 
turnover, the active site disulfide bridge at the bottom face must be reduced.6 As 
shown in figure 1-4B, a disulfide exchange between the active site disulfide bridge 
and a pair of conserved cysteines on the C-terminal tail of α32 occurs first, then 
enzyme thioredoxin (Trx) or glutaredoxin (Grx) re-reduces the consequent C-terminal 
tail disulfide bond. Trx (or Grx) would probably prefer to reduce the cysteine radical 
at the C-site (if there is any) rather than the disulfide bridge. This might explain why 
RNR utilizes a separate β-subunit to store the radical since Trx (or Grx) cannot access 
the tyrosyl radical buried inside the β-subunit.6  
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Base, nucleobases; red., reduced; ox., oxidized.  
 
Figure 1-4. Mechanistic models for A) NDPs reduction catalyzed by class I RNRs, 
and B) re-reduction of the active site disulfide bond via a pair of conserved cysteine 
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residues on the C-terminal tail, which subsequently gets re-reduced by a ubiquitous 
enzyme thioredoxin (Trx). The existence of the two disulfide bridges in the α-subunit 
was first recognized by Thelander38 in 1974. He shows that one disulfide bridge is 
formed after each NDP reduced in the E. coli class Ia system. However, two 
nucleotides can be reduced by the fully reduced enzyme in the absence of external 
reductants, indicating there are two disulfide bridges involved in the active monomer 
of E. coli class Ia RNR-α. This RNR catalysis is conserved from E. coli to H. 
Sapiens.39 The shown amino acid numbering is from E. coli Class Ia RNR system.14 
 
 In order to regenerate the active Trx (or Grx) for the next turnover, the 
oxidized Trx-S2 (or Grx-S2) is re-reduced via a redox chain shown in Figure 1-5, 
which involves the NADPH binding flavoprotein thioredoxin reductase (TrxR) (or 
NADPH binding flavoprotein glutathione reductase (GrxR)).40  
 
 
 
 
 
 
 
 
 
 
Figure 1-5. The thioredoxin system (top) and the glutaredoxin system (bottom) 
involving in RNR catalysis turnover.40  
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1.2 Allosteric regulation of class Ia RNRs 
 
 To ensure a balanced pool of deoxynucleotide monomer for DNA replication, 
the regulation of class Ia RNRs activity involves multiple allosteric sites, four different 
nucleotide effectors (ATP, dATP, dTTP, and dGTP), and changes in enzyme 
oligomeric state that accompany allosteric ligand binding.41-43 In this section, we will 
discuss how these allosteric effectors regulate enzyme activity and substrate selection. 
 To date, it seems that the formation of αn and αnβm oligomers plays an 
important role in the regulation of class I RNRs overall activity.5 Once the allosteric 
effectors (ATP, dATP, dTTP, or dGTP) bind to the S-site, RNR-α is stimulated to 
dimerize and bind to the β2 subunit to form an active α2β2 holocomplex.1,5,22 In 2006, 
Rofougaran et al28 showed that in the presence of physiological concentrations of α 
and β subunits and under the physiologically relevant conditions where both A- and S-
sites are occupied, an either active or inactive α6β2 is formed depends on whether ATP 
or dATP is bound to the A-site. The ability of ATP and dATP to induce the same 
quaternary structure but have opposing effects on RNR activity had been a conundrum 
until Fairman et al22 successfully crystallized a low-resolution (6.6 Å) X-ray structure 
of the dATP-bound hexamer from S. cerevisiae (Sc) class I RNR in 2011. Based on 
their results, the dATP-bound hexamer has a ring-like structure built up from three α-
dimers. Their cryo-electron microscopy (cryo-EM) study of the inactive α6ββʹ 
complex (in yeast, β2 is ββʹ) showed that the ββʹ subunit was bound in the center of the 
dATP-induced-ScRNR-hexamer ring, which prevents the ββʹ to interact properly to 
the α subunit. As the results, this complex is inactive because the PCET can no longer 
occur under these structural settings. Also, a formation of complex other than α6ββʹ is 
excluded in this case because only one ββʹ can be accommodated inside the α6-ring. 
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To investigate whether or not mutagenesis can target interactions at the observed 
hexamer interfaces and disrupt α-hexamerization, they also designed and purifed the 
D16R mutation in both S. cerevisiae (Sc) and human (h) RNR-α proteins. Based on 
their size exclusion chromatography (SEC) chromatograms, the D16R mutant proteins 
from both organisms cannot form dATP-induced hexamers. These results indicate that 
both ScRNR-α and hRNR-α utilize the same mechanism for dATP-induced α-
hexamerization. However, the D16R hRNR-α retained its ability to hexamerize in the 
presence of ATP. It is unfortunate that to date there is no crystal structures available 
for the ATP-induced RNR-α-hexamer. However, by using gel filtration analysis, 
Wang et al44 showed that ATP-induced α-hexamer can bind up to three p53β (an 
analogue of β in mammalian cells) dimers if the substrate analogue gemcitabine-5ʹ-
diphosphate (F2CDP) is added to the enzyme. Since a formation of an α6β6 complex 
by fitting three β2 in the center of the dATP-induced α6-ring would not be possible as 
earlier discussed22, these results altogether provided another solid evidence to support 
that ATP and dATP induce structurally different α-hexamers. Recently, Ando et al45 
crystalized a low-resolution (9.0 Å) crystal structure of the dATP-induced hRNR-α6 
where the C-sites align close to the inner hole (Figure 1-6, A–B). Based on their small-
angle X-ray scattering (SAXS) data, ATP and dATP induce hRNR-α to form a similar 
hexamer. However, addition of equimolar β to both samples led to a loss of features 
representing hexamer in ATP-treated sample, while SAXS profile of dATP-treated 
sample still shared similar features as that of the one without β subunit. To correlate α-
oligomerization with the specific activity of α, they performed assays for CDP 
reductase activity in the absence or presence of ATP or dATP. At the concentrations 
where both ATP and dATP induce hRNR-α6, determined by their SAXS profiles, α 
activity remains activated in the case of ATP, but mostly inhibited by dATP. 
Differences in the ATP- and dATP-induced α6 are thus verified. The authors also 
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proposed a model to answer a long-lasting question about why the ATP- and dATP-
induced α6 have opposing effects on α-activity (Figure 1-6C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This figure is taken and modified form Ref. 45. 
 
Figure 1-6. A) Structures of hRNR-α2 and hRNR-β2 subunits. Each monomer of 
hRNR-α2 houses three nucleotide binding sites, C-site (PDB: 3HND), A-site (PDB: 
3HNE) and S-site (PDB: 3HNC).22 Green colored ribbon structures indicate the N-
terminal ATP cone domain, where the A-site is located. Dotted lines shown in hRNR-
β2 structure represent the disordered C-terminus and N-terminus (PDB: 2UW2; To be 
published data of Welin et al). B) Crystal structure of the dATP-induced α6 (PDB: 
5D1Y).45 C) Model of the ATP- and dATP-induced α6, of which their stability is 
variable. In hRNR, binding of ATP or dATP to α subunit can promote the formation 
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of ring-shaped α6 in the absence of β2. Since the ATP-induced α6 is less stable than the 
dATP-induced α6, β2 can disrupt the ATP-induced α6 but cannot do so to the dATP-
induced α6 ring. As the results, access of β subunit to the C-site of α is prevented in the 
case of the dATP-induced α6.  
 
 In contrast to the A-site, the S-site has the ability to bind dGTP and dTTP in 
addition to ATP and dATP. Specificity of NDP substrate binding to the C-site depends 
on the occupancy of this site. Binding of ATP or dATP to this site stimulates reduction 
of CDP or UDP at the C-site, while binding of dGTP and dTTP direct the enzyme 
toward to reduction of ADP and GDP, respectively.1,4,5,43 This general model for 
substrate selection is well-supported by biochemical and structural data.4,22,46-51  
 Originally, it was unclear how the effectors bound to the S-site direct substrate 
binding since these two sites are approximately 15 Å apart from each other.4 But, now, 
since many crystal structures of RNRs in the presence of allosteric effectors and 
substrates available22,47-50,52, it is unambiguous that the S-site communicates with the 
C-site via a flexible loop 2 (residues 289–303 in E. coli or 283–298 in humans), which 
bridges these two sites48 (Figure 1-7). When the allosteric effector binds to the S-site, 
the conformation of loop 2 is changed in such a way that it affects the C-site 
conformation in a highly specific manner, making it prone to bind one substrate over 
the others.4, 5 Loop 2, as a consequence, becomes more ordered after the effector and 
substrate binding.48,50 In addition to loop 2, there is an additional loop, so-called loop 1 
(residues 259–278 in E. coli) (Figure 1-7), located near the S-site and is stabilized 
upon the effector binding.50  
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This figure is taken and modified from Ref. 48.  
 
Figure 1-7. Ribbon representation of two subunits in the E. coli class Ia RNR, A) α-
subunit (PDB: 3R1R)50 and B) β-subunit (PDB: 1RIB)15. In A), NDP substrate and 
dNTP specific effector are shown as spheres in yellow and purple, respectively. 
Orange spheres represent C439, where the active site thiyl radical is formed. Loop 1 
and loop 2 are colored in red. In B), one β chain is colored in orange and the other is in 
tan. Green spheres represent the diiron cofactor needed for the initial tyrosyl radical 
generation. C) Sequence alignment of loop 2 residues of characterized class Ia, class 
Ib, and class II RNRs. The absolutely conserved residues are highlighted.  
 
 In 2016, Zimanyi et al48 determined their crystal structures of E. coli class Ia 
RNR with all four pairs of specificity effector–substrate bound (dATP–CDP, dATP–
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UDP, TTP–GDP, and dGTP–ADP), and revealed the conformational rearrangements 
responsible for this allostery (Figure 1-8). Based on their composite omit electron 
density maps, they confirm that loop 2 is ordered after effector and substrate bind to 
the enzyme (Figure 1-8, left panels). The results also show a stabilized loop 2 that 
adopts three different conformations depending on which specific effector is bound to 
the S-site. In brief, dATP can hydrogen bond to S293, which subsequently makes 
Q294 orienting toward the C-site and stabilizing the binding of both CDP and UDP 
(Figure 1-8, A–B). Since cytidine deaminase provides another level of control for 
dCTP/TTP ratios, this lack of discrimination between CDP and UDP substrates by 
RNR should not be troublesome.53,54 In contrast to dATP, binding of dGTP hydrogen 
bonds to Q294 and pulls it away from the C-site, creating a more expansive C-site for 
the larger purine substrates to bind and hydrogen bond to the carbonyl of G299. Even 
though binding of CDP and UDP is not prohibited in this case, the CDP/UDP binding 
would not be stabilized due to the absence of Q294 at the C-site (Figure 1-8, A–C). 
Likewise, binding of TTP to the S-site creates room at the C-site for purine substrates, 
even though TTP does not direct hydrogen bond to Q294 (Figure 1-8D). Specificity 
for ADP versus GDP appears to be modulated by the position of the carbonyl of G299. 
If effector-loop contact stabilizes the carbonyl of G299 in a forward position, ADP is 
favored, whereas stabilizing the carbonyl of G299 in a backward position favors GDP 
(Figure 1-8, C–D). Among the differences discussed above, R298 of loop 2 always 
forms a conserved charge-charge interaction with the β-phosphate of all four 
substrates.  
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This figure is taken and modified from Ref. 48.  
 
Figure 1-8. Conformations of E. coli RNR loop 2 in the presence of specificity 
effector–substrate pairs: A) dATP–CDP (PDB: 5CNS) B) dATP–UDP (PDB: 5CNT) 
C) dGTP–ADP (PDB: 5CNU), and D) TTP–GDP (PDB: 5CNV). Left panels show 
composite omit electron density maps. Carbon, oxygen, nitrogen, and phosphorus are 
colored in yellow, red, blue, and orange, respectively. Right panels, on the other hand, 
show 2D representations of hydrogen-bonding interactions.  Each residue is colored 
  17 
differently and residues 295–297 are shown as a black line. Hydrogen bonds are 
indicated with black dashed lines.  
 
  Soon after, Knappenberger et al51 provided further information how functional 
groups of each specific effector drive hRNR substrate specificity. Based on crystal 
structures of eukaryotic class Ia RNRs bound to S-site effectors from previous 
studies22,47 (Figure 1-9, A–C) and the sequence alignment of loop 2 across species 
(Figure 1-7C), there are three conserved amino acid residues, Q288, G289, and R293 
(hRNR numbering), and one non-conserved amino acid residue, D287, proximal to the 
effector nucleobase. Similar to the results observed from E. coli RNR, binding of 
different specific effector affects the conformation of loop 2 in different way (Figure 
1-9, A–C). In a crystal structure of hRNR with dTTP bound to the S-site (Figure  
1-9A), the nucleobase does not contact D287 directly. Instead, the N3 group of dTTP 
contacts N270 that forms a hydrogen bond with D287.47,55,56 In the structure of ScRNR 
containing dGTP in the S-site, the protonated N1 group of dGTP forms a hydrogen 
bond to the carboxylic acid side chain of D287 (Figure 1-9B). In contrast, the 
unprotonated N1 group of the adenosine nucleobase in the structure of ScRNR 
containing AMPPNP in the S-site acts as a hydrogen bond acceptor and contacts the 
backbone amide group of D287. The D287 side chain, in this case, is pointed away 
from the S-site (Figure 1-9C).47,57 Until the study of Knappenberger et al, the 
functional groups proposed to drive substrate specificity had remained untested.  To 
determine the molecular features of specific effectors that contribute to substrate 
discrimination, the authors examined hRNR substrate specificities directed by a series 
of purine and pyrimidine effector analogues using internal competition kinetics. Based 
on their results, the 5-methyl, O4 and N3 groups of dTTP direct specificity for GDP, 
whereas the exocyclic amine of dCTP acts as an antideterminant for overall effector 
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function. The O6 and protonated N1 of dGTP contribute to specificity for ADP, the 
unprotonated N1 of dATP, on the other hand, is the primary determinant for CDP 
substrate (Figure 1-9D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/A, non-applicable; Figure A–C are taken and modified from Ref. 51. 
 
Figure 1-9. A–C) Structures of eukaryotic RNRs bound to S-site effectors. A) Crystal 
structure of hRNR bound to dTTP and GDP (not shown) (PDB: 3HND).22 B) Crystal 
structure of ScRNR bound to dGTP and ADP (not shown) (PDB: 2CVX).47 C) Crystal 
structure of ScRNR bound to AMPPNP and CDP (not shown) (PDB: 2CVU).47 S-site 
effectors are shown as dark blue sticks. Small spheres represent atoms that perturb 
specificity when modified. Loop 2 amino acids are shown as white sticks, while the 
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conserved Q288, G289, and R293 are shown as red sticks. Yellow dashes indicate 
potential contacts involving the non-conserved D287. Optimal substrate in response to 
the binding of each nucleotide effector is shown in D). R denotes the deoxyribose 
triphosphate moiety, except that ATP has a ribose triphosphate moiety.   
 
1.3 Formation of tyrosyl radical in class Ia RNR β subunit 
 
 The tyrosyl radical needed for RNRs (class Ia) catalytic cycle is generated in β 
subunit by the reaction of the diiron (II) cluster with O2, according to equation 1.1 (Eq. 
1.1). This equation describes the four-electron reduction of O2 to its oxidation state 
O2– in the best-studied E. coli β-subunit.58 While the total of three electrons are 
obtained from the bound diiron cluster and Y12259, another electron is from an 
external source, i.e., exogenous Fe(II)6,60 or a ferrous ion in the diiron site of the 
second β-subunit.6,58 
 
          [Y122, FeII−FeII] + O2 + e−                    [Y122 , FeIII−O−FeIII] + OH−     (Eq. 1.1) 
 
 It is known that the activation of dioxygen by a ferrous diiron center is not 
unique for RNR-β. Very similar ferrous diiron centers are also found in other proteins 
such as the hydroxylase component of methane monooxygenase (MMOH) and  
Δ9 stearoyl-acyl carrier protein desaturase. These proteins not only bind dioxygen, but 
also have very similar overall protein fold pattern. In most cases, the dioxygen is 
cleaved and used in the catalysis. However, in the oxygen carrier protein hemerythrin, 
the binding of dioxygen is reversible.61-63  
 The stable diferrous state, FeII−FeII, in E. coli β2 is formed after adding ferrous 
ions to the apo protein under anaerobic conditions (Figure 1-10).6,64 In 1996, Logan et 
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al reported the X-ray structure of this diferrous form of E. coli β2 with 1.7-Å 
resolution.65 Fe1 and Fe2 appear to coordinate with one histidine, H118 and H241, 
respectively. E115 and E238 bridge the two iron ions by using both oxygens from 
their carboxylic acid moieties. The distance between these iron ions (3.9 Å) is 
increased from what previously observed in the met state of RNR-β, which is a non-
radical FeIIIFeIII state (3.3 Å).15 The last ligand coordination of Fe1 and Fe2 is from a 
monodentate terminal ligand, D84 and E204, respectively. Due to their coordination 
number (n=4), these iron ions could be described as distorted tetrahedrons. 
 Under aerobic conditions, the molecular oxygen (O2) will bind to diferrous β-
subunit, generating a diferrous-oxygen complex. Though, a crystal structure of such 
complex has yet been observed in RNRs.6 However, the indirect evidence for the 
existence of this intermediate is found in MMOH.62,66   
 Based on the homology between RNR-β and related diiron center containing 
proteins, it could be expected that oxygen atoms from O2 instantly abstract an electron 
from each Fe(II) when it binds the diferrous center, forming a µ-1,2-peroxy diferric 
intermediate (A).63,67 The homolytic O−O cleavage of this peroxo complex initially 
requires an electron from each Fe(III), leading to the formation of diiron(IV) 
intermediate B. This intermediate is stable in the absence of methane or other 
oxidizable substrates.61,62,68 Again, the formations of these two intermediates have not 
yet been observed in RNR. 
 As intermediate B is considered as a very strong reductant, it can oxidize 
amino acid residues with sufficiently low redox potentials residing close to the diiron 
center, e.g., tryptophans and tyrosines. W48, a member of the radical transfer chain, 
provides an electron to cleave the nearest O−FeIV bond, generating intermediate C.59,69 
This red-colored intermediate has been observed in the reconstitution reaction of wild-
type RNR-β under limiting iron source (less than 2.4 irons per β-subunit).70 However, 
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the lifetime of this intermediate is too short to be observed when the reconstitution 
reaction is carried out under excessive amount of iron (more than five irons per β-
subunit).71 This could be explained by the fact that an exogenous Fe(II) immediately 
transfers an electron to W48+ and, thus, intermediate D is directly observed. 
Intermediate D is stable for a few seconds time-scale. However, in the Y122F mutant 
where the key Y122 is replaced with non-oxidizable phenylalanine, the lifetime of 
intermediate D is doubled.70-72  
 By abstracting a hydrogen atom from a phenolic hydroxyl group in Y122, the 
iron site is left in the active FeIII−O−FeIII form and a stable tyrosyl radical (Y122) is 
observed. After this reconstitution process, the stable inactive met RNR-β state and an 
intermediate mixed valence FeIIFeIII state can be generated in vitro.6  
 All crystal structures of oxidized RNR-β have been of the met RNR-β state 
since this state is spontaneously obtained upon storing purified iron-containing protein 
in solution. However, selective reduction of Y122 by exogenous reductants, i.e., 
hydoxyurea73,74, various hydrazines75,76 and alkoxyphenols77, can also lead to the met 
RNR-β state formation.   
 Ascorbate or dithionite are used as reducing reagents to transfer an electron to 
the met RNR-β state, generating the mixed valence FeIIFeIII state in mouse and herpes 
simplex type 1 RNR-β.6,78 In the wild-type E. coli RNR-β, however, this mixed 
valence state has been observed after reduction by hydrazines at high pH6,75 and 
radiolytic reduction at 77 K.6,79-81 Up to date, no crystal structures of this FeIIFeIII state 
from any organism have been obtained.  
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Figure 1-10. Formation of the stable tyrosyl radical in E. coli β-subunit.6  
  
 The docking models of crystal structures of E. coli RNR-α and RNR-β have 
shown that the radical of Y122 in RNR-β needs to be transferred no less than 35 Å to 
C439 at the C-site in RNR-α.8,82 Kolberg et al6 states that this unusual long radical 
transfer distance “is far beyond the reach of the pure electron tunnelling process found 
in most other biological electron transfer reactions”. So, this radical has been proposed 
to be concertedly transferred via a chain of hydrogen bonded amino acid side chains 
instead.83-87  
 In order to understand the mechanism of this long-range PCET pathway in E. 
coli class Ia RNR, many studies have been actively refining our understanding of the 
residues involved.11,84,88,89 These studies include site-directed mutagenesis90,91, site-
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specific replacement of Y356-β, Y730-α, and Y731-α with unnatural tyrosine 
analogues with modified redox properties81,92, distance measurement between residues 
involved in the radical propagation pathway using pulsed-electron double resonance 
(PELDOR) spectroscopy93, and others. The most recent study of Kasanmascheff and 
co-workers94 in 2016 proposed a more detailed mechanism of PCET, involving a so-
called “flipped” conformation of Y731-α (Figure 1-11). They believe that the 
flexibility of Y731-α and Y356-β, which is located in the flexible C-terminal tail of β2 
subunit, might be the key to drive the radical transfer at the subunit surface through 
water cluster.95,96 Of note, these two contiguous residues have been suggested to 
communicate during PCET.97  
  
 
  
 
 
 
 
 
 
 
 
 
This model is adapted from Ref. 94. 
 
Figure 1-11. Model for long-range (~35 Å), reversible radical transfer in E. coli class 
Ia RNR. The locations of Y356 and E350 are unknown since they are within the 
flexible C-terminal tail of β2.  W48, D237, and E350 are shown in grey because there 
is no published experimental data that supports their participation in this process.94 
Red, blue and purple arrows represent electron transfer, proton transfer and collinear 
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PCET pathways, respectively. The green tyrosine moiety shows the flipped 
conformation of Y731.  
 
1.4 Inhibitors of class Ia RNRs  
 
 In 1953, Irwin and Schweigert98 observed that dNTPs cannot be directly 
obtained from cell metabolism, but instead are synthesized from NTPs through 
catalytic reduction performed by RNRs. As DNA replication and repair are dependent 
on the availability of adequate and balanced pools of dNTPs99, inhibition of RNRs can 
induce cell apoptosis.12  
 To form active RNRs, class Ia enzymes require subunit interactions, free 
radical chemistry, metallocofactor, and redox-active sulfhydryl (–SH) groups in the α 
subunit. Thus, to date, there are at least six important and useful types of inhibitors 
that could potentially inhibit class Ia RNRs in various ways (Figure 1-12).12,61  
 
 
 
 
 
 
 
 
 
Figure 1-12. Six potential types of class Ia RNRs inhibitors.12,61  
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 As the metallocofactor is indispensable for the radical formation in the β 
subunit, type I inhibitors inhibit enzyme activity by chelation of the cofactors either in 
solution (preventing the incorporation of the cofactor in the enzyme) or directly at the 
enzyme-bound metal center.12 Some examples of this type include Triapine (3-
aminopyridine-2-carboxaldehydethiosemicarbazone)100, deferrioxamine (DFO)101, and 
2-hydroxy-1-naphthylaldehydeisonicotinoyl hydrazine102. Type II inhibitors diminish 
enzyme activity by donating electrons to quench the crucial tyrosyl radical, which is 
buried ~10 Å from the surface of the protein. In order to approach the free radical, 
these radical scavengers are normally small and planar12, e.g., hydroxyurea (HU)103, 
acetohydroxamate104, hydroquinone, and hydrazine derivatives105. Even though some 
inhibitors from type I and type II have already been largely used in cancer treatment, 
they have a main common disadvantage due to a short half-life of β subunit. As they 
will have time enough to find its target only in tumors that have an accelerated growth 
rate, their application is limited.12 Type III inhibitors are nucleoside analogues that 
have similar chemical structures to ATP and are capable of inhibiting RNRs, e.g., 
Cladribine (ClA)106,107, Fludarabine (FlU)108, and Clofarabine (ClF)12,109. Beside ClF, 
which inhibits RNR by alternation of RNR-α’s quaternary structure25,27, how the 
others inhibit RNR remained unknown by the time we started our study. Type IV 
inhibitors, which are oligopeptides, prevent the formation of an active α2β2 
holocomplex. These inhibitors exert their inhibition by competing with the β-subunit, 
via sequence homology to the β subunit’s nine C-terminal residues. Some examples of 
type IV inhibitors for mammalian class Ia RNRs110 are shown in Figure 1-13.  Type V 
inhibitors are small compounds that can covalently modify sulfhydryl groups of the 
active site cysteines. One of the most popular is caracemide (CAR or N-acetyl-N,O-
di(methylcarbamoyl)-hydroxylamine) (Figure 1-13).12 CAR irreversibly inactivates 
the α-subunit of E. coli RNR, probably at an activated cysteine or serine residue, but 
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does not have any observable effects on the β subunit. The active α2β2 complex, 
nevertheless, is more sensitive to CAR than the α subunit alone.111 Type VI inhibitors, 
the so-called “suicide inhibitors”, are recognized by RNRs as natural substrates. 
However, when they react with the C-site, they lead to abnormal products that 
subsequently inactivate the enzyme activity. Examples of this type include 
arabinosylcytosine (ara-C)112, azidouridine113, gemcitabine (F2C)114,115 and other.12  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-13. Examples of class Ia RNRs inhibitors.12, 61, 110  
   
 According to the US Food and Drug Administration (FDA), many drugs have 
been moved into clinical trials without understanding how they act, which sometimes 
leading to failures in late-stage clinical trials.116 Thus, understanding a drug’s 
mechanism could potentially help guide drug development. As mentioned above, there 
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were some type III RNR inhibitors of which their enzyme inhibition mechanisms had 
been unknown until this study, e.g., ClA and FlU. Since di- and triphosphate of ClF 
have been shown to inhibit RNR by inducing RNR-α-subunit-hexamerization both in 
vitro and in cell25,27, in this study we hypothesize that ClA and FlU might inhibit RNR 
via the same mechanism as ClF based on their similarities in structures as well as 
applications for the treatment of leukemia.117  
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 CHAPTER 2 
 
Nucleotide Syntheses  
 
2.1 Introduction 
 
Nucleoside analogues in cancer therapy 
 
 Many cellular processes, e.g., cell signaling, enzyme regulation and 
metabolism, demand nucleosides and nucleotides.1 Particularly, during cell division, 
dNTPs are necessary for DNA and RNA synthesis. Maintaining balanced dNTP pools 
is thus pivotal for genomic stability since mutagenesis can be caused by 
misincorporation of an excess dNTP into DNA.2 
 The development of anticancer and antiviral drugs has been focused on the 
design and synthesis of chemically modified nucleosides and nucleotides, so-called 
nucleoside analogues. These agents have been developed to mimic physiological 
nucleosides and nucleotides and thus compete with their counterparts as 
antimetabolites.1,3 By incorporation of nucleoside analogues into DNA and RNA, cell 
proliferation and viral replication can be inhibited.1 Both pyrimidine and purine 
nucleoside analogues such as Cytarabine (Cytosar-U®), Gemcitabine (Gemzar®), 
Clofarabine (Clolar®), Cladribine (Leustatin®), Fludarabine (Fludara®) and 
Troxacitabine (Troxatyl™) are currently clinically used as antimetabolite drugs.4 
 Besides of behaving as antimetabolites, Gemcitabine (F2C) and Clofarabine 
(ClF) (Figure 2-1) were shown to have inhibitory activity towards enzyme 
ribonucleotide reductase (RNR) through different mechanisms (Figure 2-2).5-10 While 
gemcitabine 5′-diphosphate (F2CDP) is a potent mechanism-based inhibitor of class I 
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and II RNRs7, di- and triphosphates of ClF were the first group of nucleotide-based 
drugs that reversibly inhibit RNR by inducing RNR-α-subunit-hexamerization.8   
 
 
 
 
 
 
Figure 2-1. Structures of RNR-inhibiting nucleoside analogues of which mechanisms 
are know in vitro (F2C)5,6 as well as in cells (ClF)8-10 and unknown ClA and FlU2,4. 
 
 In order to prove that this reversible mechanism is not limited to ClF, we 
sought for other nucleoside analogues that might have the ability to induce this RNR-
α–subunit oligomeric regulation. ClF was developed after other deoxyadenosine 
analogues, ClA and FlU.11,12 All of these adenosine analogues are shown to kill 
lymphocytes selectively.13 As they have halogenated substitution at C2 of adenine ring 
(Figure 2-1), these agents are resistant to adenosine deaminase, a catabolic enzyme 
that may diminish the quantity of the active nucleoside analogues1,4,14 (Figure 2-3). In 
addition to sharing the same adenosine backbone structure, these three compounds 
have been shown to target enzyme RNR and have similar effectiveness against 
hematologic malignancies (Table 2-1).4,11,15-21  
 In this work, by considering their similar structures, therapeutic functions, and 
common target enzyme, ClA and FlU were then hypothesized to reversibly inhibit 
enzyme RNR via the same oligomeric regulation as ClF. 
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i) Irreversible inhibition of α2β2 holocomplex by F2CDP (active form of F2C in cell)5-7 
 
 
 
 
 
 
PCET, Proton-Coupled Electron Transfer. 
 
ii) hRNR-α specific oligomeric regulation by ClA(D/T)P (active forms of ClF in cell).8-10 
 
 
 
 
 
 
Figure 2-2. F2C (i) and ClF (ii) inhibit RNR via distinct mechanisms. 
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Figure 2-3. Mechanism of nucleoside analogues’ activity in cell. Figure adapted from 
Ref. 1.  
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Table 2-1. Postulated target enzyme(s) and therapeutic function of triphosphorylated 
ClF, ClA and FlU. Adapted from Ref. 4. 
 
 
 
 
 
 
 
TP, triphosphorylated nucleoside analogue. 
 
Active forms of nucleoside analogues in cell 
 
 Cytotoxicity of nucleoside analogues is mainly associate with accumulation of 
their phosphorylated derivatives in cells4,13,22-24 (Figure 2-3). Enzymes involved in the 
phosphorylation steps of ClF, ClA and FlU are listed in Table 2-2.  Of note, 
fludarabine is clinically used in its monophosphorylated form (FlUMP). The 
additional phosphate group is important for drug solubility. However, FlUMP is 
dephosphorylated by plasma phosphatases and ecto-5′-nucleotidase to FlU right before 
it gets transported into cells by nucleoside transporters. Following entry into cells, FlU 
is initially phosphorylated to FlUMP by enzyme dCK, prior to further phosphorylation 
to FlUDP or FlUTP by other kinases.4 Since dCK plays key roles in these drugs’ 
activations, either by (1) providing a monophosphate metabolite reservoir for their di- 
and triphosphate active forms (for ClF and ClA)23 or (2) catalyzing the rate-limiting 
step in FlU’s activation23,25 (Table 2-2), cell lines with drastically decreased level of 
dCK are resistant to these drugs.26-28 In order to study the mechanism(s) through 
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which ClA and FlU inhibit RNR in vitro, the di- and triphosphorylated forms of ClA 
and FlU were synthesized in this thesis study. Monophosphorylated nucleoside 
analogues are not the primary focus of this thesis since RNRs bind to only nucleoside 
di- and triphosphates.     
 
Table 2-2. Enzymes involved in cellular phosphorylation steps of ClF, ClA and FlU. 
 
 
 
 
 
 
 
 
dCK, deoxycytidine kinase; MP, monophosphorylated nucleoside; DP, diphosphorylated nucleoside; 
TP, triphosphorylated nucleoside.  
 
Synthesis of nucleoside monophosphates (NMPs) in the literature 
 
 Synthetic approaches for nucleoside 5′-monophosphates have been developed 
by using either a P(III) or P(V) reagent as a phosphate source. The corresponding 
intermediates are shown in Figure 2-4.29  
 
 
 
 
 
 
  43 
 
 
 
 
 
 
 
Nu, nucleoside; R1 and R2, alkyl groups.  
 
Figure 2-4. P(III) and P(V) intermediates formed during monophosphorylation of 
nucleosides. Adapted from Ref. 29. 
 
 In 1967, Yoshikawa and co-workers reported a 5′-monophosphorylation of 
unprotected natural nucleosides. For substrate adenosine, phosphoryl chloride in 
triethylphosphate is used as a phosphate source and the reaction is carried out at 0−4 
°C for 6 hours before hydrolysis (Scheme 2-1).30 Formation of a nucleoside-
trialkylphosphate complex (1) explains the reaction’s regioselectivity.30,31 However, 
formation of hydrochloric acid (HCl) during hydrolysis of 2 to NMPs could 
potentially lead to the acid-catalyzed cleavage of the glycosidic bond. Thus, 
triethylammonium bicarbonate (TEAB) buffer is used to maintain the reaction pH 
~7.5.29   
 
 
 
 
 
  44 
 
 
 
 
 
Scheme 2-1. Synthesis of monophosphorylated adenosine (AMP) using Yoshikawa’s 
method.30 
 
 Nevertheless, Yoshikawa’s method might not be ideal for nucleoside 
analogues of which their C2′ substituents are electronegative elements; for example, 
F2C (Figure 2-1). By having fluorines nearby, the C3′ hydroxyl group is acidic enough 
to initiate C3′, C5′-cyclic phosphate formation from unprotected nucleoside32 (Figure 
2-5). 
 
 
 
B, nucleobase. 
 
Figure 2-5. Structure of C3′, C5′-cyclic phosphate nucleoside.32  
 
 In 2000, Taktakishvili and Nair developed another phosphorylating reagent, 2-
O-(4,4′-dimethyoxytrityl)ethylsulfonylethan-2′-yl-phosphate (3) for phosphorylation 
of the primary and secondary alcohol of deoxyribonucleosides in the present of a 
coupling reagent, triisopropylbenzenesulfonyl tetrazolide (TPS-TAZ)29,33 (Scheme  
2-2). Syntheses of deoxynucleoside monophosphates (dNMPs) are accomplished after 
in situ deprotection of protecting groups at the phosphate and C3′ hydroxyl groups in 
80−95% yield.33  
 
B, 
Nucleoba
se 
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Scheme 2-2. Syntheses of dNMPs using an alternative phosphorylating reagent 3.33 
 
 A drawback of this method is that protection for both the nucleobase and C3′ 
hydroxyl groups is required before the phosphorylation step (Scheme 2-2).33  
 As NMPs are synthesized in cells by nucleoside kinases4,12,15,22-24,29, enzymatic 
syntheses of NMPs have also been reported. In 1997, Usova and Eriksson 
accomplished phosphorylation of nucleoside derivatives by using human 
deoxycytidine kinase (dCK) and a phosphate donor molecule, ATP.34 In 2011, the 
same method was applied to ClFMP synthesis.8 As ClF and ClA are both adenosine 
derivatives, human dCK was used to synthesize ClAMP in this present work under an 
assumption that the enzyme’s catalytic function would remain for ClA substrate.  
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Synthesis of nucleoside diphosphates (NDPs) in the literature 
 
 Synthesis of NDPs via phosphorodichloride intermediate (2), by using a 
corresponding precursor based on Yoshikawa’s method (Scheme 2-1), has been 
reported (Scheme 2-3). Tetra-n-butyl ammonium phosphate is used as a phosphate 
donor in this approach. After hydrolysis by TEAB buffer, NDP is obtained. However, 
the presence of a triphosphate derivative byproduct is reported in some cases.29   
 
 
 
 
 
Scheme 2-3. NDP synthesis via NMP precursor obtained from Yoshikawa’s 
procedure. Adapted from Ref. 29. 
 
 There are other approaches for NDP syntheses reported; for example, synthesis 
via a tosylate intermediate by the Poulter group35 and synthesis via a phosphoramidate 
intermediate.36,37 However, these approaches require either days for reaction 
completion or protecting groups at C2′ and/or C3′ hydroxyl groups. Moreover, all 
studies mentioned above reported only phosphorylation of natural (d)NMP substrates. 
Nucleoside derivatives that contained a modified base have not been studied. 
 Aye and Stubbe have developed a synthetic route to synthesize ClFDP from its 
precursor (ClFMP) after many of their attempts to utilize nucleotide monophosphate 
kinases failed (Scheme 2-4).8 Before the addition of a phosphorylating agent, 
tributylammonium phosphate (TBAP), the phosphate group of ClFMP is initially 
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activated by carbonyl diimidazole (CDI) to form 10 (Scheme 2-4).8,36 An advantage of 
this method is that there is no triphosphorylated byproduct observed.  
 
 
 
 
 
 
Scheme 2-4. ClFDP synthesis. Adapted from Ref. 8.  
 
Synthesis of nucleoside triphosphates (NTPs) in the literature 
 
 In 1981, Ludwig revealed a route to synthesize (deoxy)adenosine 5′-
triphosphates. The first step is (d)AMP synthesis using Yoshikawa’s procedure 
(Scheme 2-1 and 2-5). Addition of tributylamine and an excess of bis(tri-n-
butylammonium) pyrophosphate in dry DMF for 1 minute leads to a formation of 
cyclic 11. Final product, (d)ATP, is obtained after hydrolysis with 1 M TEAB in 
excellent yield.38  
 
 
 
 
 
B, nucleobases; A, adenine. 
 
Scheme 2-5. (d)ATP synthesis. Adapted form Ref. 29 and 38. 
  48 
 Aye and Stubbe also applied this method to their ClFTP synthesis shown in 
Scheme 2-6.8   
 
 
 
 
 
 
Scheme 2-6. ClFTP synthesis. Adapted from Ref. 8. 
  
 By taking structural similarity between ClF, ClA and FlU into account, Aye 
and Stubbe’s procedure was chosen to be a synthetic route for di- and 
triphosphorylation of ClAMP and FlUMP in this work (Scheme 2-7). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2-7. Enzymatic synthesis of monophosphate of ClA and chemical syntheses 
of di- and triphosphates of ClA and FlU.  
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2.2 Experimental 
 
General Materials and Methods. Cladribine (ClA), Fludarabine phosphate (FlUMP) 
and Clofarabine (ClF) were from AK Scientific. Streptomycin sulfate and isopropyl β-
D-thiogalactopyranoside (IPTG) were purchased from Gold Biotechnology. DL-
dithiothreitol (DTT) was from Amresco. All other chemicals were purchased from 
either Sigma Aldrich or Fisher in highest available purity and used without further 
purification. Sephadex G-25 resin for protein purification, DEAE-Sephadex A-25 
chloride, TALON® metal affinity resin and Dowex® 50WX4 200−400 (H) were from 
GE Healthcare, Sigma life science, Clontech and Alfa Aesar, respectively. Centricons 
were from Millipore. The human deoxycytidine kinase (dCK) expression plasmid was 
kindly provided by Professor Staffan Eriksson (Swedish University of Agricultural 
Sciences, Uppsala, Sweden).34 Analytical thin layer chromatography (TLC) was 
performed on Merck TLC silica gel 60 F254 glass plates. Compounds were visualized 
by exposure to UV light. Enzyme human dCK concentration was determined using its 
known absorption property: A280nm = 1.0 at 0.55 mg/mL. Gel images were analyzed 
using Image Lab Version 4.1. Concentrations of ClA(M/D/T)P, FlU(M/D/T)P and 
ClF(M/D)P were determined by using their extinction coefficients: ε265, ClA = 15,700 
M-1.cm-1, ε263, FlU = 16,400 M-1.cm-1 and ε263, ClF = 16,400 M-1.cm-1, respectively.  
 
Purification of enzyme human deoxycytidine kinase (dCK) 
 
 The His6-tagged human dCK plasmid34 was transformed into the BL21-
CodonPlus(DE3)-RIL E.coli host strain, selected with kanamycin, and inoculated in 
Luria Broth (LB) containing 50 µg/mL Kanamycin and 50 µg/mL Chloramphenicol. 
The expression of human dCK was induced when the OD600 reached 1.0 by the 
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addition of IPTG, to a final concentration of 1.0 mM. The media was incubated for 
another 4 hours at 37 °C. Cells were then harvested by centrifugation at 6,000×g for 
20 minutes at 4 °C. This cell pellet preparation was performed by a former member of 
the Aye lab, Tyler Charles Peterhansel. The expression of human dCK was confirmed 
by SDS-PAGE gel (Figure 2-6).  
 Purification of His6-tagged human dCK was carried out by a modified 
procedure of Usova and Eriksson.34 The cell pellet was suspended in lysis buffer (20 
mM Tris-HCl pH 7.9, 500 mM NaCl, 10 mM imidazole, 10 mM BME and 0.5 mM 
PMSF) in a ratio of 1 g cell pellet:5 mL lysis buffer. The suspension was then lysed at 
13,000 psi by two passes through a French Pressure Cell Press. After centrifugation at 
20,000×g at 4 °C for 30 minutes, streptomycin sulfate was slowly added to the 
supernatant to a final concentration of 2% (wt/v) within 15 minutes. The suspension 
was then gently stirred and incubated at 4 °C for another 15 minutes. The supernatant 
obtained after centrifugation at 20,000×g at 4 °C for 30 minutes was incubated with 
TALON® metal affinity resin, which was pre-equilibrated with 10 column volumes 
(CV) of lysis buffer, for 1 hour. The suspension was re-loaded on the column and the 
flow through was collected for SDS-PAGE. The resin was washed with 1 bed volume 
(BV) of wash buffer (20 mM Tris-HCl pH 7.9, 500 mM NaCl, 50 mM imidazole and 
10 mM BME) to get rid of any non-specific binding proteins. This step was repeated 
two more times.  Elution buffer (20 mM Tris-HCl pH 7.9, 500 mM NaCl and 150 mM 
imidazole) was then used to elute human dCK; 1.5 mL fractions were collected to a 
final volume of 48 mL. Fractions that had A280nm:A260nm ratios greater than 1.6 were 
pooled. Centricons with a membrane NMWL (nominal molecular weight limit) of 10 
kDa were used to concentrate protein-containing fractions to a final volume of 9 mL 
before loading onto Sephadex G-25 resin, which had been pre-equilibrated with at 
least 5 BV of storage buffer (20 mM Tris-HCl pH 7.9, 500 mM NaCl, 10 mM DTT 
  51 
and 20% glycerol). After elution, the protein-containing fractions, judged by Bradford 
protein assay39,40, were concentrated using 10 kDa NMWL centricons to a final 
concentration of 5.1 mg/mL. His6-tagged human dCK concentration was calculated 
using A280nm = 1.0 at 0.55 mg/mL. The purity of the enzyme was determined using 
SDS-PAGE (Figure 2-6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-6. SDS-PAGE gels of (left) His6-tagged human dCK expression induced by 
IPTG and (right) purified His6-tagged human dCK (30 kDa34). 
 
Syntheses of ClFMP, ClFDP, ClAMP, ClADP, ClATP, FlUDP, and FlUTP  
 
ClFMP and ClFDP. Mono- and diphosphorylated ClF were synthesized as previously 
reported.8 Anion exchange chromatography (DEAE-Sephadex) of the reaction of ClF 
with His6-tagged human dCK and of the reaction of ClFMP with TBAP are shown in 
Figure 2-7 and 2-8, respectively. NMR spectroscopic, both 1H and 31P, and mass 
spectrometric analyses were verified with previously reported spectra.8  
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Figure 2-7. Anion-exchange purification of ClFMP. 
 
 
 
 
 
 
 
 
Figure 2-8. Anion-exchange purification of ClFDP. 
 
ClAMP. The conversion of substrate ClA to ClAMP was achieved via enzymatic 
phosphorylation using human dCK (Scheme 2-7).8,34 The 10 mL reaction mixture, 
containing 1 mM ClA, 10 mM ATP, 2 mM DTT, 100 mM KCl and 10 mM MgCl2 in 
Tris-HCl (pH 7.6), was gently stirred at 37 °C for 2 minutes before His6-tagged human 
dCK was added, to a final concentration of 0.25 mg/mL. The reaction was further 
incubated at 37 °C for another 45 minutes. Completion of the reaction was confirmed 
by silica gel TLC using 10% MeOH in ethyl acetate as the mobile phase.  Anion-
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exchange purification of ClAMP on 40 mL BV of DEAE A-25 Sephadex column, 
which had been pre-equilibrated with 200 mL of 5 mM TEAB (pH 7.0), was carried 
out at 4 °C. After a 150 mL×150 mL linear gradient from 5 mM to 400 mM TEAB 
(pH 7.0) was applied to the A-25 Sephadex column, the desired product was eluted 
(Figure 2-9). Product-containing fractions were pooled and solvent removed under 
vacuum using a lyophilizer.  
 
ClADP. The triethylammonium salt (Et3NH+) of ClAMP (5.9 µmol) was dissolved in 
500 µL H2O and loaded onto 60 mL BV of Dowex® 50WX4 200−400 (H) column, 
which had been pre-equilibrated with 600 mL (or 10 BV) of 20% pyridinium (pyH+) 
solution. The pyH+ salt of ClAMP was eluted with H2O and solvent removed under 
vacuum using a lyophilizer. The resultant salt (pyH+ of ClAMP) was dissolved in  
1 mL H2O, then treated with 12 µmol of (n-Bu)3N. The reaction mixture was 
azeotroped with benzene (5×1.5 mL) to provide the anhydrous tributylammonium [(n-
Bu)3NH+] salt of ClAMP. 100 µL of anhydrous dimethylformamide (DMF) was added 
to the (n-Bu)3NH+ salt of ClAMP (3.4 µmol) under argon (Ar) atmosphere, followed 
by CDI (16.8 µmol) in 100 µL DMF at room temperature (RT). The resultant clear 
solution was stirred overnight under Ar atmosphere at RT. Then, excess CDI was 
consumed by the addition of anhydrous MeOH (3 µmol). The suspension was further 
stirred at RT for 30 minutes before 32 µL of 0.27 M solution of TBAP (prepared as 
previously reported)8,41,42 was added. The reaction suspension was stirred at RT for 
another 10 minutes at which point the reaction container was placed in a desiccator 
under house vacuum until dry-residue was observed. 200 µL of DMF was added to the 
resultant residue. After centrifugation (20,850×g, 1 minute, at RT), the supernatant 
was collected. The process was repeated 6 times before the combined supernatants 
were treated with an equal volume of MeOH, and subsequently concentrated in vacuo. 
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After dissolving the residue in 1 mL ddH2O, ClADP was purified at 4 °C on 20 mL 
BV of DEAE-Sephadex A-25 column that had been pre-equilibrated with ddH2O. 
ClADP was eluted with a 150 mL×150 mL linear gradient from 0 M to 1 M TEAB 
(pH 7.0). 5 mL fractions were collected and assayed for A260nm and A280nm (Figure  
2-10). After pooling all ClADP-containing fractions, the solvent was removed using a 
lyophilizer.  
 
ClATP. 5 µmol of anhydrous (n-Bu)3NH+ salt of ClAMP was dissolved in anhydrous 
DMF (330 µL). 25 µmol CDI in 170 µL of anhydrous DMF was then added to the 
resultant cloudy suspension. After stirring at RT under Ar atmosphere for 19 hours, a 
colorless solution was obtained. The excess CDI was quenched by the addition of 
anhydrous MeOH (192 µmol), and was stirred for another 30 minutes. The resultant 
solution was treated with a 0.1 M solution of a commercially available 
tributylammonium pyrophosphate (TBAPP, 25 µmol) in anhydrous DMF, which had 
been freshly prepared. The resultant suspension was stirred at RT for another 10 
minutes before placing it under vacuum overnight. Anion exchange chromatography 
of ClATP was carried out at 4 °C on a 20 mL BV DEAE-Sephadex A-25 column, 
which had been pre-equilibrated with ddH2O. Upon applying a 200 mL×200 mL linear 
gradient from 0 to 1 M TEAB (pH 7.0) onto the column, 5 mL fractions were 
collected and assayed for A260nm and A280nm (Figure 2-11). The solvent was removed 
under vacuum using a lyophilizer after all ClATP-containing fractions were pooled.  
 
FlUDP. The commercially available FlUMP (31.8 µmol) was dissolved in 1 mL of  
5 mM TEAB (pH 7.0) and subsequently loaded on a 40 mL BV of DEAE-Sephadex 
A-25 column, which had pre-equilibrated with 200 mL of 5 mM TEAB (pH 7.0). This 
step was carried out at 4 °C. The desired product was eluted with a 150 mL×150 mL 
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linear gradient from 5 mM to 400 mM TEAB (pH 7.0). 6 mL fractions were collected 
and assayed for A260nm and A280nm (Figure 2-12). The solvent was removed under 
vacuum using a lyophilizer. The resultant Et3NH+ salt of FlUMP was evenly separated 
into three portions. Each portion was dissolved in ddH2O and loaded on a 60 mL BV 
of Dowex® 50WX4 200−400 (H) column, which had been pre-equilibrated with 600 
mL of 20% pyridinium (pyH+) solution. ddH2O was then used to elute the desired 
pyH+ salt of FlUMP. All fractions containing the pyH+ salt of FlUMP from three 
separate batches were combined and the solvent was removed using a lyophilizer. 13.6 
µmol of the resultant pyH+ salt of FlUMP was dissolved in 1 mL ddH2O, followed by 
treatment with 27 µmol of (n-Bu)3N. In order to obtain the anhydrous (n-Bu)3NH+ salt 
of FlUMP, the reaction mixture was azeotroped with benzene (5×1.5 mL). The 
amount of (n-Bu)3NH+ salt of FlUMP was determined by using ε263, FlU = 16,400 M-
1cm-1, and found to be 12.1 µmol. The synthesis of FlUDP was consequently 
accomplished by following the same protocol as mentioned in ClADP synthesis. A 20 
mL BV of DEAE-Sephadex A-25 column was used for the purification of FlUDP. The 
column was pre-equilibrated with ddH2O before use. The temperature during the 
purification process was kept constant at 4 °C. A sequence of different concentrations 
of TEAB (pH 7.0) used to elute the desired product comprised of a 150 mL×150 mL 
linear gradient from 0 to 300 mM TEAB (pH 7.0), an isocratic flow of 100 mL of 300 
mM TEAB (pH 7.0), and a 200 mL×200 mL linear gradient from 300 to 700 mM 
TEAB (pH 7.0). 5 mL fractions were collected and assayed for A260nm and A280nm 
(Figure 2-13). After pooling all FlUDP-containing fractions, the solvent was removed 
under vacuum using a lyophilizer.  
 
FlUTP. The protocol, identical to that of ClATP synthesis, was followed starting with 
7.2 µmol of anhydrous (n-Bu)3NH+ salt of FlUMP. The triphosphate of FlU was eluted 
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from a DEAE-Sephadex A-25 column with a 200 mL×200 mL linear gradient from 0 
to 1 M TEAB (pH 7.0). 5 mL fractions were collected and assayed for A260nm and 
A280nm (Figure 2-14). FlUTP-containing fractions were pooled and subsequently 
solvent removed under vacuum using a lyophilizer.  
 
2.3 Results and discussion 
 
ClAMP. After lyophilizing the ClAMP-containing fractions (Figure 2-9), the resultant 
white powder (59 % isolated yield) was characterized by 1H and 31P NMR 
spectroscopic analyses: 1H NMR (600 MHz, D2O) δ (ppm) 8.38 (s, 1H), 6.38 (t, 3J = 
6.8 Hz, 1H), 4.65−4.71 (m, 1H), 4.22−4.28 (m, 1H), 4.02 (m, 2H); 31P NMR (501 
MHz, D2O, H3PO4 external reference) δ 2.02 ppm (see Appendix B). HRMS (ESI) 
exact mass calculated for C10H12ClN5O6P [M-H]- requires m/z: 364.02192, found 
364.02231.  
 
 
 
 
 
 
 
 
Figure 2-9. Anion-exchange purification of ClAMP using DEAE-Sephadex A-25 
column. 
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ClADP. As shown in Figure 2-10, ClADP was eluted at 550 mM TEAB. The final 
product after lyophilizing, with overall 56% yield, was characterized by 1H, 31P NMR 
spectroscopic, and mass spectrometric analyses: 1H NMR (600 MHz, D2O) δ (ppm) 
8.45 (s, 1H), 6.43 (t, 3J = 6.8 Hz, 1H), 4.74−4.78 (m, 1H), 4.30 (m, 1H), 4.10−4.20 (m, 
2H); 31P NMR (501 MHz, D2O, H3PO4 external reference) δ (ppm) -10.53 and -11.11; 
(see Appendix B); HRMS (ESI) exact mass calculated for C10H13ClN5O9P2 [M-H]- 
requires m/z: 443.98825, found 443.98973.  
 
 
 
 
 
 
 
 
Figure 2-10. Anion-exchange purification of ClADP. 
 
ClATP. The desired triphosphate of ClA was eluted at 630 mM TEAB (Figure 2-11). 
The resultant lyophilized residue, in overall 69% yield, was evaluated by 1H, 31P NMR 
spectroscopic, and mass spectrometric analyses: 1H NMR (600 MHz, D2O) δ (ppm) 
8.50 (s, 1H), 6.46 (t, 3J = 6.8 Hz, 1H), 4.31−4.33 (m, 1H), 4.15−4.28 (m, 2H), 
4.10−4.20 (m, 2H); 31P NMR (400 MHz, D2O, H3PO4 external reference) δ (ppm)  
-10.54, -11.23 and -23.10 (see Appendix B); HRMS (ESI) exact mass calculated for 
C10H14ClN5O12P3 [M-H]- requires m/z: 523.95458, found 523.95505. 
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Figure 2-11. Anion-exchange purification of ClATP. 
 
FlUDP. As described above, the diphosphate of FlU was synthesized from the 
lyophilized FlUMP-containing fractions (Figure 2-12). During the anion-exchange 
purification, FlUDP was eluted at 300 mM TEAB (Figure 2-13). The overall 13% 
yield material was characterized by 1H, 31P NMR spectroscopic, and mass 
spectrometric analyses: 1H NMR (600 MHz, D2O) δ (ppm) 8.43 (s, 1H), 6.34 (d, 3J = 
5.9 Hz, 1H), 4.61 (t, 3J = 6.2 Hz, 1H), 4.49 (t, 3J = 6.7 Hz, 1H), 4.32 (m, 2H), 4.19 (m, 
1H); 31P NMR (501 MHz, D2O, H3PO4 external reference) δ (ppm) -10.24 and -11.01 
(see Appendix B); HRMS (ESI) exact mass calculated for C10H13FN5O10P2 [M-H]- 
requires m/z: 444.01272, found 444.01374.  
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Figure 2-12. Anion-exchange chromatography (DEAE-Sephadex A-25) of FlUMP. 
 
 
 
 
 
 
 
 
 
Figure 2-13. Anion-exchange (DEAE-Sephadex A-25) purification of FlUDP. 
 
FlUTP. Shown in Figure 2-14, FlUTP-containing fractions were eluted at 600 mM 
TEAB (pH 7.0). The 13% lyophilized material was judged homogenous by 1H, 31P 
NMR spectroscopic, and mass spectrometric analyses: 1H NMR (600 MHz, D2O) δ 
(ppm) 8.63 (s, 1H), 6.35 (d, 3J = 6.0 Hz, 1H), 4.62 (t, 3J = 6.4 Hz, 1H), 4.49 (t, 3J = 7.0 
Hz, 1H), 4.34 (m, 2H), 4.19 (m, 1H); 31P NMR (501 MHz, D2O, H3PO4 external 
reference) δ (ppm) -10.47, -11.07, and -22.95 (see Appendix B); HRMS (ESI) exact 
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mass calculated for C10H14FN5O13P3 [M-H]- requires m/z: 523.97905, found 
523.96014. 
 
 
 
 
 
 
 
 
Figure 2-14. Anion-exchange purification of FlUTP. 
 
Conclusions 
 
 Phosphorylated derivatives of ClA and FlUMP were successfully synthesized 
and characterized for a variety of in vitro biochemical studies. One advantage of using 
enzymatic phosphorylation is the enzyme’s specificity towards its substrates, which 
circumvents the protection and deprotection steps used in standard chemical 
phosphorylation methods. Additionally, since enzymatic reactions do not generate any 
undesired byproducts, the reaction-yields tend to be much higher. Even though the 
syntheses of FlUDP and FlUTP were not achieved in high yields, this method was 
relatively straightforward and facile, when compared with other chemical methods.35-37  
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 CHAPTER 3 
 
In Vitro Biochemical Studies of Di- and Triphosphates of Cladribine  
and Fludarabine [ClA(D/T)P and FlU(D/T)P] 
 
3.1 Introduction  
 
 Due to the key role of ribonucleotide reductase (RNR) in DNA synthesis and 
cell growth control1, a wide range of strategies has been developed to inhibit RNR 
activity. Many known inhibitors are nucleoside analogues, of which their 5ʹ-
diphosphate (for class I and some class II RNRs) or 5ʹ-triphosphate (for class III and 
some class II RNRs)2,3 forms can act as mechanism-based or competitive inhibitors  
(Figure 3-1).4-6 One of the most successful mechanism-based inhibitors that have 
developed into anti-tumor agents is gemcitabine (2ʹ,2ʹ-difluorodeoxycytidine, F2C).7-9  
 
 
 
 
 
 
Figure 3-1. Some nucleoside analogue inhibitors of RNRs. Their active forms are 
either the 5ʹ-diphosphates (for class I and some class II RNRs) or the 5ʹ-triphosphates 
(for class III and some class II RNRs).4-6  
 
 In 2005, Cerqueira et al5 proposed a mechanism by which gemcitabine 
5ʹ-diphosphate (F2CDP) utilizes to inhibit RNR activity in the absence of exogenous 
reductants (Figure 3-2). This mechanism is proposed based on density functional 
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theory (DFT) computational calculations modeling only the ribose ring (without base, 
pyrophosphates, or C5ʹ included) and key C-site side chains (cysteines as CH3SH and 
the glutamate as formate), not the fully active catalytic site (C-site). The authors 
proposed a stable C4ʹ radical (J) to be a final product of this mechanism. However, the 
possibility of the top-face cysteine abstracting the C4ʹ-hydrogen atom (I) to generate 
the C4ʹ radical (J) is later ruled out by the crystal structures of substrate-bound class I 
RNR-α.10,11 These structures provide little support for the possibility that the C3ʹ-keto 
nucleotide remains in the C-site long enough for the abstraction of the C4ʹ-hydrogen 
atom. Instead, it is most likely released from the C-site and decomposes into furarone, 
which subsequently alkylates the enzyme as has been shown in the case of 2ʹ-chloro-
2ʹ-deoxyuridine12 (Figure 3-3).  
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C (at the enzyme catalytic site), cysteine; E, glutamic acid; C (attached to a ribose ring), cytosine; PP, 
pyrophosphate. 
 
Figure 3-2. Inhibitory mechanism of RNR by F2CDP proposed by Cerqueira et al.5  
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C (at the enzyme catalytic site), cysteine; E, glutamic acid; C (attached to a ribose ring), cytosine; PPi, 
inorganic pyrophosphate. 
 
Figure 3-3. Upon a release of the C3ʹ-keto nucleotide from the C-site (state I in Figure 
3-2), it decomposes in solution into furanon,  which subsequently alkylates the RNR-
α.6,10-12  
 
 In addition to mechanism-based inhibitors that bind at the C-site of RNRs, 
there are also some synthetic nucleoside analogues that contain deoxyadenosine 
moiety similar to an enzyme inhibitory allosteric effector (dATP), i.e., Clofarabine 
(ClF), Cladribine (ClA), and Fludarabine (FlU) (Figure 3-4). These compounds not 
only provide a potential RNR allosteric inhibition, but also have a low affinity to 
nucleotide-catabolizing enzymes such as adenosine deaminase, resulting in resistance 
to cell inactivation.1 Their resistance to those catabolic enzymes arises from a 
halogenated substitution at C2 of their adenosine ring (Figure 3-4).13-15  
 
 
 
 
 
 
Figure 3-4. Chemical structures of dATP and its nucleoside analogues.  
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 Mechanism(s) by which these three deoxyadenosine analogues use to inhibit 
RNR had been unknown until Aye and Stubbe16 revealed a breakthrough on how ClF 
inhibits human (h)RNR in 2011. They have shown that di- and triphosphate of ClF 
induce inactive hRNR-α-hexamers (hRNR-α6) (see Figure 2-2, chapter 2). This 
mechanism is different from the one used by F2CDP in two main aspects. First, it does 
not require the β-subunit. Second, this inhibition is reversible. As ClF, ClA, and FlU 
share a few common characteristics with respect to their structures and clinical use as 
antileukemic drugs14,17-25, we hypothesized that these three deoxyadenosine analogues 
inhibit RNR via the same mechanism.  
 In this chapter, we report various in vitro experiments/techniques used to 
determine whether and how these di- and triphosphates of Cladribine and Fludarabine 
inhibit human RNR (hRNR) activity. For example, rapid CDP reductase activity 
assays16,26 was used for the quantification of their binding affinities to the enzyme, 
fluorescence resonance energy transfer (FRET)27, size exclusion chromatography 
(SEC) and electron microscopy (EM) were used for the determination of their 
enzyme-oligomerization inducing ability, and fluorescence anisotropy assays were 
used for the identification of their enzyme binding site preference, etc. Detailed 
explanations of all in vitro experiments are provided in the experimental section 3.2.2.  
 
3.2 Experimental 
 
General Materials and Methods. 5-iodoacetamidofluorescein (5-IAF) and 
tetramethylrhodamine-5-iodoacetamide dihydroiodide (5-TMRIA) were from 
Invitrogen. Texas Red®-5-dATP (T*-dATP) was obtained from PerkinElmer®. 
Streptomycin sulfate and isopropyl β-D-thiogalactopyranoside (IPTG) were from Gold 
Biotechnology. DL-dithiothreitol (DTT) and sodium phosphate monobasic 
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monohydrate were obtained from Amresco. 7-amino-4-methylcoumarin (AMC) was 
purchased from Alfa Aesar. N-alpha-CBZ-arginine 7-amino-4-methylcoumarin 
hydrochloride (z-Arg-AMC) was purchased from Santa Cruz Biotechnology. Alkaline 
Phosphatase Calf Intestinal (CIP) (10,000 U/mL) was from New England Biolabs. 
Sequencing grade modified trypsin was purchased from Promega. All other chemicals 
were obtained from either Sigma Aldrich or Fisher in highest available purity and used 
without further purification. NH4+ salt of [5-3H]-CDP (19.4 Ci/mmol) was from 
ViTrax. AG® 1-X8 resin acetate form was purchased from BioRad. PD-10 desalting 
columns, Sephadex G-25 resin and protein molecular weight (M.W.) standards were 
from GE Healthcare. DEAE-Sephadex A-25 chloride and TALON® metal affinity 
resin were from Sigma life science and Clontech, respectively. Ultrafiltration 
membranes (YM-30 and -10), Centricons and Minicons were from Millipore.   
 Gel images were analyzed using Image Lab Version 4.1. The 3H-counting was 
operated using LS 6500 multipurpose Scintillation Counter (Beckman Coulter). 
Absorbances were measured using a UV-2600 spectrophotometer from Shimadzu.  
Curve fittings and data analyses were evaluated using Prism v6.0 and v7.0 (Graphpad) 
and Kaleida Graph Version 4.1.2 (Synergy Software). Fluorescence anisotropy assays 
were performed using Varian Cary Eclipse Fluorescence Spectrophotometer. In 
fluorescence resonance energy transfer (FRET) experiments, fluorescence intensities 
were measured using Cytation™ 3 from BioTek®.  
 ClFTP and F2CDP used in these studies were previously synthesized and 
determined the concentrations using extinction coefficients previously reported.16,27,28 
Concentrations of ClA(M/D/T)P, FlU(M/D/T)P and ClF(M/D)P were determined by 
using their extinction coefficients: ε265, ClA = 15,700 M-1.cm-1, ε263, FlU = 16,400 M-1.cm-1 
and ε263, ClF = 16,400 M-1.cm-1, respectively. 
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General Mammalian Expression Plasmids. Expression plasmids encoding E. coli 
thioredoxin A (His6-Trx)27, hRNR α-subunit (His6-α)27, hRNR β-subunit (His6-β)27, 
hRNR D57N α-subunit (His6-D57N-α)16 and the N-terminal domain of hRNR α-
subunit (His6-H-NTD)29 were generous gifts from different sources (see references).  
 
3.2.1 Protein purifications and their activity tests 
 
General Recombinant Protein Expressions. Plasmid containing gene of interest was 
transformed into BL21-CodonPlus(DE3)-RIL competent cells, or non-codon enhanced 
BL21 competent cells in the case of His6-Trx. Cells were grown at 37 °C overnight on 
an LB-agar plate containing 50 µg/mL Kanamycin. A single colony was picked and 
inoculated in 5 mL LB containing 50 µg/mL Kanamycin (and 50 µg/mL 
Chloramphenicol if CodonPlus cells were used).  The culture tube was incubated 
overnight at 37 °C before diluting into 1.2 L LB media containing 50 µg/mL 
Kanamycin. Once OD600 reached 0.6–0.8, 1.0 mM IPTG (or 0.3 mM in the case of 
His6-β and His6-Trx) was added to induce the expression of a desired protein. The 
media were incubated at 19 °C for another 16 hours (or at 30 °C for 6 hours in the case 
of His6-β.30 Cells were then harvested by centrifugation for 20 minutes at 4 °C 
(6,000×g). The expression of desired protein was confirmed by 10% SDS-PAGE gel 
(or 15% SDS-PAGE gel for His6-Trx and His6-H-NTD). 
 
General Protein Purifications. All buffer components used to purify protein of 
interest are listed in Table 3-1. The cell pellet was suspended in lysis buffer in a ratio 
of 1 g cell pellet:5 mL lysis buffer. The suspension was then lysed at 13,000 psi by 
two passes through a French Pressure Cell Press. After centrifugation at 20,000×g at 4 
°C for 30 minutes, streptomycin sulfate was slowly added to the supernatant to a final 
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concentration of 2% (wt/v) within 15 minutes. The suspension was then gently stirred 
and incubated at 4 °C for another 15 minutes. The supernatant obtained after 
centrifugation at 20,000×g at 4 °C for 30 minutes was incubated with TALON® metal 
affinity resin, which was pre-equilibrated with 10 column volumes (CV) of lysis 
buffer, for 1 hour. The suspension was re-loaded on the column and the flow through 
was collected for SDS-PAGE. The resin was washed with 1 bed volume (BV) of wash 
buffer to get rid of any non-specific binding proteins. This step was repeated two more 
times.  Elution buffer was then used to elute desired protein; 1.5 mL fractions were 
collected to a final volume of 48 mL. Fractions that had A280nm:A260nm ratios greater 
than 1.6 were pooled. 30 kDa (or 10 kDa for His6-Trx and His6-H-NTD) molecular 
weight cut-off Centricons were used to concentrate protein-containing fractions to a 
final volume of 9 mL before loading onto Sephadex G-25 resin, which had been pre-
equilibrated with at least 5 BV of storage buffer. After elution, the protein-containing 
fractions, judged by Bradford protein assay31,32, were concentrated using centricons. 
The enzyme purities were determined using SDS-PAGE (Figure 3-5, 3-7, 3-9, 3-10 
and 3-12). 
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Table 3-1. Buffer components for each protein purification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** His6-TrxR was purified and tested its activity by Saba Parvez, a Ph. D. candidate 
in the Aye Lab. 
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hRNR α-subunit (His6-α). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5. 10% SDS-PAGE gel of purified His6-α (90 kDa). 
 
Activity test. In 1970, Steeper and Steuart reported a rapid assay to measure RNR 
activity in mammalian cell extracts using a tritium (3H)-labeled CDP substrate. The 
enzyme activity was determined based on the amount of 3H-dCDP produced at certain 
incubation time. Upon loading the reaction mixture on borate column, which had been 
pre-equilibrated with saturated K2B4O7 and rinsed off the excess salt with water, all 
vicinal diols left in the assay mixture were trapped. The amount of 3H-dCDP was then 
determined by using liquid scintillation counting.26  
 Later, Aye and Stubbe16 adapted this assay to study the binding affinity of di- 
and triphosphorylated Clofarabine [ClF(D/T)P] for purified recombinant RNR 
(Scheme 3-1).  
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DP, diphosphate; PP, diphosphate; C, cytidine; dC, deoxycytidine; A, adenosine; dA, deoxyadenosine. 
Scheme 3-1. A CDP reductase assay used to determined hRNR activity in vitro.  
 
 In order to determine a reductase activity of purified recombinant RNR-α, Aye 
and Stubbe’s protocol16 was followed. Typical assay mixture (AM) for CDP reduction 
in a 135 µL final volume contained: assay buffer (AB) [50 mM Hepes (pH 7.6),  
15 mM MgCl2, 3 mM ATP, 2 mM NADPH, 200 µM E. coli Trx, 1 µM E. coli TrxR, 
0.5 mM [5-3H]-CDP [specific activity (SA): 21,532 cpm.nmol-1], 0.3 µM hRNR-α and 
2.1 µM hRNR-β. The AM without the substrate was incubated at 37 °C for 2 minutes 
before the nucleotide reduction was initiated by the substrate addition. 30 µL-aliquots 
were removed at four different time points (40, 80, 130 and 180 seconds) post 
initiation, and immediately quenched with 30 µL 2% (v/v) HClO4. The pH of the 
reaction mixture was neutralized by adding 30 µL of 0.4 M NaOH. Dephosphorylation 
of the resultant [5-3H]-dCDP was achieved by adding 410 µL of dephosphorylation 
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mixture containing 10 units calf intestinal alkaline phosphatase (CIP), 1.2 mM 
deoxycytidine (dC), 100 mM Tris-HCl (pH 8.6), and incubating the mixture at 37 °C 
for 2 hours. [5-3H]-C and adenosine were separated from the resultant mixture by 
loading 450 µL of the mixture on a borate column (prepared as previously 
described26), followed by an addition of 7.55 mL of ddH2O. 1 mL of the [5-3H]-dC 
solution was mixed with 9 mL scintillation cocktails. The amount of [5-3H]-dC, which 
referred to the [5-3H]-dCDP formed, at each time point was then analyzed by liquid 
scintillation counting.   
 
 
 
 
 
Unit, nmol.min-1. 
Figure 3-6. Purified recombinant hRNR-α activity test. The specific activity (SA) was 
calculated from the slope of the fitting curve. 
  
 This batch of hRNR-α was shown to have a specific activity (nmol.min-1.mg-1) 
of 148 unit.mg-1, for the reduction of [5-3H]-CDP to [5-3H]-dCDP. 
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His6-D57N-α. 
 
 
 
 
 
 
 
 
Figure 3-7. 10% SDS-PAGE gel of purified His6-D57N-α (90 kDa). 
 
Activity test. The same protocol as described in hRNR-α activity test was followed. 
However, 0.3 µM D57N-α was used instead of 0.3 µM hRNR-α. 
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Unit, nmol.min-1. 
Figure 3-8. Purified recombinant D57N-α activity test. The specific activity (SA) was 
calculated from the slope of the fitting curve.  
 
 Based on the activity curve shown above, this batch of D57N-α showed an SA 
for the reduction of [5-3H]-CDP to [5-3H]-dCDP of 325 unit.mg-1. 
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His6-H-NTD. 
 
 
 
 
 
 
 
 
Figure 3-9. 15% SDS-PAGE gels of (left) purified His6-H-NTD (11 kDa) (right) and 
a comparison between His6-H-NTD and His6-Trx (14 kDa). 
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hRNR β-subunit (His6-β). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10. 10% SDS-PAGE gel of purified His6-β (45 kDa). 
 
Reconstitution of hRNR-β.33,34 Stock apo-hRNR-β was diluted with argon (Ar)-
saturated hRNR-β storage buffer (Table 3-1) to make a roughly 55 µM apo-hRNR-β. 
The resultant solution was then degased by exposing the solution to Ar for 30 seconds 
before switching to a vacuum for a second. This step was repeated 5 times before the 
solution was left under Ar atmosphere during the last cycle. The resultant mixture was 
gently added 22 µM ferrous ammonium sulfate hexahydrate (Mohr’s salt), and 
incubated for another 20 minutes under anaerobic condition before O2 saturated 
storage buffer was added. The amount of O2 saturated storage buffer needed was 
calculated as previous reported.30 The reaction mixture was then loaded onto the G-25 
column, which had been pre-equilibrated with at least 4 CV of hRNR-β storage buffer. 
  81 
Protein-containing fractions, determined by Bradford dye31,32, were pooled and 
concentrated using centricons. All steps mentioned above were carried out on ice (or 
at 4 °C).  
 
Verification of tyrosine radical in hRNR-β.35 Electron paramagnetic resonance (EPR) 
spectra of the reconstitutued RNR-β were collected at the National Biomedical 
Research Center for AdvanCed ESR Technology (ACERT) at Cornell University. 
Instrument settings were as following: sweep time, 61 seconds; time constant, 0.163 
seconds; modulation amplitude, 1.0 G; modulation frequency, 100 kHz; microwave 
power, 25 dB (0.6325 mW); temperature, 50 K. An average spectrum was calculated 
from 10 scans. The tyrosyl free radical in a 45 µM reconstituted hRNR-β sample was 
compared with a 45 µM E. coli RNR-β standard sample, which was purified and 
reconstituted by William A. Blessing (Figure 3-11). 
 
 
 
 
 
 
 
 
 
Figure 3-11. Overlaid EPR spectra of tyrosyl radicals from the reconstituted human 
(blue) and E. coli (black) RNR-β (45 µM) recorded at 50 K.  
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 The EPR pattern of the reconstituted hRNR-β was similar to the previously 
reported EPR signal of a tyrosyl radical in hRNR-β.34,36 This indicated the presence of 
the tyrosyl radical in the sample.  Moreover, the activity of this reconstituted hRNR-β 
was confirmed by its significantly increased signal intensity compared to the standard 
sample.  
   
His6-Trx.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-12. 15% SDS-PAGE gel of purified His6-Trx (14 kDa). 
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Activity test. Ellman’s reagent or 5,5'-dithio-bis-(2-nitrobenzoic acid) (DTNB) was 
used as a substrate in Trx activity assay (Figure 3-13).  
 
 
 
 
 
 
 
 
 
 
Figure 3-13. Introduction of thioredoxin (Trx) activity assay.37  
 
 Typical AM for Trx activity assay contained in a 300 µL final volume of  
100 mM Tris-HCl (pH 8.0), 25 mM EDTA, 0.1 µM E. coli TrxR, 0.1 mM NADPH, 
0.15 mM DTNB and 25 µM E. coli Trx. The AM without E. coli Trx was incubated at 
37 °C 1 minute prior to the addition of E. coli Trx. For blank, the protein storage 
buffer was used instead of E. coli Trx. Absorbance at 412 nm (A412nm) of AM was 
collected throughout all time using a UV-2600 spectrophotometer (Shimadzu). By 
plotting A412nm against incubation time, the amount of TNB2- generated per second 
was calculated by using TNB2- molar extinction coefficient (ε0): 14,150 M-1.cm-1.38 
(Figure 3-14).  
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Figure 3-14. Thioredoxin (Trx) activities were reproducible among 4 technical 
replicates. The averaged activity of this batch of Trx was 95 unit.mg-1, or 1 mg of Trx 
can reduce DTNB to 95 nmol TNB2- in one minute. 
 
3.2.2 In vitro biochemical studies of ClA(D/T)P and FlU(D/T)P 
 
Radioactive assays for [5-3H]-CDP reduction in isolate system 
 
Dose-dependent inhibition assays for wild-type (wt) hRNR-α and D57N-α (Figure  
3-21 and 3-35). Typical inhibition mixture (IM) in a 50 µL final volume contained  
3 mM ATP, 2 mM NADPH, 15 mM MgCl2, 0.5 mM [5-3H]-CDP, 100 µM E. coli Trx, 
1 µM E. coli TrxR, 3 µM hRNR-β, 1 µM wt hRNR-α (or D57N-α) in 50 mM Hepes 
(pH 7.6). The IM without [5-3H]-CDP was pre-incubated at 37 °C for 2 minutes prior 
to the addition of substrate and a particular inhibitor (ClADP, or ClATP, or FlUDP, or 
FlUTP) at various concentrations (as shown in Figure 3-21). After further incubation 
at 37 °C for 3 minutes, 30 µL of 2% (v/v) HClO4 was added to quench the enzymatic 
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reaction and the reaction pH was subsequently neutralized by adding 30 µL of 0.4 M 
NaOH. Upon adding 390 µL of dephosphory-lation mixture [10 units CIP, 1.2 mM 
dC, 100 mM Tris-HCl (pH 8.6)] and incubating the mixture at 37 °C for 2 hours, all 
phosphorylated nucleotides got dephosphorylated. The amount of [5-3H]-dC was 
analyzed as described under hRNR-α activity test. To derive an inhibition constant (Ki) 
of each nucleotide analogue, in the case of wt hRNR-α, the obtained data were fitting 
to the tight-binding equation (Eq. 3.1)39.  
 
                                                           (Eq. 3.1) 
 
 In this equation, υ0 and υi represent enzyme activity in the absence or in the 
presence of inhibitor at particular concentration, respectively; [E]T represents the total 
concentration of enzyme; [I]T represents the total concentration of inhibitor; and Ki 
represents an inhibition constant. 
 
Time-dependent inhibition assays for wt hRNR-α (Figure 3-22). Typical IM in a 250 
µL final volume contained 3 mM ATP, 2 mM NADPH, 15 mM MgCl2, 0.5 mM  
[5-3H]-CDP, 100 µM E. coli Trx, 1 µM E. coli TrxR, 3 µM hRNR-β, 1 µM hRNR-α 
and a particular concentration of nucleotide inhibitor [ClADP (5 µM), ClATP (5 µM), 
FlUDP (50 µM), or FlUTP (12.5 µM)] in 50 mM Hepes (pH 7.6). The IM without  
[5-3H]-CDP was pre-incubated at 37 °C for 2 minutes prior to the addition of the 
substrate. After further incubation at 37 °C, 30 µL-aliquots of IM were taken out at 
different time points (0, 0.5, 1, 3, 7, 10 and 15 minutes) and immediately quenched 
with 30 µL of 2% (v/v) HClO4. The reaction pH was then neutralized by an addition of 
0.4 M NaOH (30 µL). Dephosphorylation of [5-3H]-dCDP and a measurement of the 
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amount of [5-3H]-dC generated were achieved as previously described under hRNR-α 
activity test. 
 
Time-dependent inhibition assays for hRNR-β subunit 
 
 Two mixtures required for this assay were separately prepared. First, a typical 
IM in a final volume of 70 µL (for Triapine® (3-AP), FlUDP, FlUTP and control) or 
35 µL (for ClADP and ClATP) contained 2 µM hRNR-α, 2 µM hRNR-β, 3 mM ATP, 
15 mM MgCl2, 10 mM DTT, 6 µM of indicated inhibitor or buffer alone (for control) 
in 50 mM Hepes (pH 7.6). Second, a typical AM in a final volume of 21 µL (for 3-AP, 
FlUDP, FlUTP and control) or 57 µL (for ClADP and ClATP) contained 3 µM hRNR-
α (for 3-AP, FlUDP, FlUTP and control) or 2 µM hRNR-α (for ClADP and ClATP),  
3 mM ATP, 15 mM MgCl2, 2 mM NADPH, 0.5 mM [5-3H]-CDP, 100 µM E. coli Trx, 
1 µM E. coli TrxR in 50 mM Hepes (pH 7.6). The IM without inhibitor was pre-
incubated at 37 °C for 2 minutes prior to the addition of a particular inhibitor (or 
buffer for control). At the designated time points, 9 µL (for 3-AP, FlUDP, FlUTP and 
control) or 3 µL (for ClADP and ClATP) aliquots were removed from IM and 
subsequently diluted into the AM, which had been pre-incubated at 37 °C for  
2 minutes. Subsequent to 3-minute incubation period, the reaction was quenched with 
30 µL of 2% (v/v) HClO4 and the pH was neutralized by adding 30 µL of 0.4 M 
NaOH. Dephosphorylation of [5-3H]-dCDP was achieved by adding 410 µL (for 3-AP, 
FlUDP, FlUTP and control) or 380 µL (for ClADP and ClATP) of dephosphorylation 
mixture containing 10 units CIP, 1.2 mM dC, 100 mM Tris-HCl (pH 8.6). After  
2-hour incubation period at 37 °C, the amount of [5-3H]-dC was analyzed as described 
under hRNR-α activity test. 
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Fluorescence Resonance Energy Transfer (FRET)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D, donor molecule; A, acceptor molecule; ex, excitation; em, emission. 
 
Figure 3-15. Diagram depicting a FRET experiment. This figure is adapted from Ref. 
40.  
 
 Clegg describes FRET as a spectroscopic process by which energy is non-
radiatively transferred over long distances (10–100 Å) between molecules. In this 
process, the donor molecule, which must be a fluorophore, absorbs a photon from an 
external source and transfers this energy non-radiatively to the acceptor molecule.40 
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The efficiency of energy transfer really depends on the distance between the two 
interacting molecules as well as the overlap of the donor molecule emission and the 
acceptor molecule excitation spectra (Figure 3-15). The more overlap the spectra, the 
better the efficiency of energy transfer. 
 In general, the donor-acceptor pairs can be free in solution, one or both 
(covalently or noncovalently) bound to a macromolecule, or be an inherent part of the 
structure.40 In 2014, Yuan et al27 developed a FRET reporter platform using 5-IAF 
labeled hRNR-α as the donor molecule and 5-TMRIA labeled hRNR-α as the acceptor 
molecule to report hRNR-α hexamerization induced by dATP, ClFDP or ClFTP 
(Figure 3-16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-16. Introduction of the FRET-quenching assay reporting the ligand-driven 
hRNR-α oligomerization. The ribbon structure represents the known 9.01 Å dATP-
bound human α6 crystal structure (PDB: 5D1Y).41  
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Fluorescence dye labeling of hRNR-α. A labeling reaction mixture in a 250 µL final 
volume contained 10 µM hRNR-α, 30 µM 5-IAF or 30 µM 5-TMRIA, 15 mM MgCl2, 
1 mM DTT in 50 mM Hepes (pH 7.6). The reaction mixture was incubated under dark 
at RT for 20 minutes. The excess fluorescence dye was removed by using a PD-10 
Sephadex G-25M column, which had been pre-equilibrated with AB [15 mM MgCl2 
and 5 mM DTT in 50 mM Hepes (pH 7.6)]. Upon adding AB, 5-IAF labeled hRNR-α 
(F-α) or 5-TMRIA labeled hRNR-α (T-α) was eluted out of the column. Labeled-
protein containing fractions, judged by Bradford protein assay31,32, were pooled and 
adjusted to a final concentration of 1 µM using AB. Labeled proteins were 
immediately carried out onto subsequent FRET assay.  
 
Spectrofluorometer-based FRET assay. 220 µL of 0.2 µM fluorescence dye labeled 
protein was prepared by mixing F-α and T-α in a 1:5 ratio and adjusting the volume 
with AB. For titration experiments, a minimum volume of ClADP or ClATP was 
titrated into a 3 mm×3 mm path length quartz fluorescence microcuvette to make a 
final concentration of nucleotide inducer of 50, 100 and 250 µM. In control 
experiment, the same volume of nucleotide inducer was replaced with 20 mM Hepes 
(pH 7.6). Fluorescence intensities were measured using a Varian Cary Eclipse 
spectrofluorometer with the following settings: excitation wavelength, 480 nm; 
recorded emission spectra, 505–620 nm; excitation slit width, 20 nm; emission slit 
width, 10 nm. The emission spectra of oligomeric assembly were recorded after 
incubation at RT for 2, 4, 5, 6, and 8 minutes. 
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Figure 3-17. FRET quenching assays reporting ClAD(T)P-induced hRNR-α 
oligomerization. In control experiment, ClAD(T)P was replaced with the same volume 
of buffer to report fluorescence quenching caused by volume changes. These data 
were measured after incubation at RT for 5 minutes.  
 
 Upon titration of ClADP or ClATP up to 250 µM, fluorescence signal of F-α 
was quenched by 32% and 26%, respectively. On the other hand, only 7% of this 
quenching was from the change in assay volume (Figure 3-17). These results 
suggested that ClADP and ClATP were able to induce hRNR-α oligomerization. 
Various incubation time points (2, 4, 5, 6, or 8 minutes) were also examined; however, 
there was no significantly difference in fluorescence signals observed among each 
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time point (see Appendix C). This informed us that the nucleotide-induced hRNR-α 
oligomerization reached its equilibrium within 2-minute timescale. Even though we 
observed promising results from these preliminary experiments, performing FRET 
assays in the microcuvette might not be ideal since it requires a lot of enzyme and 
nucleotide inducers. We then took advantage of a Biotek Cytation™ 3 plate-reader in 
order to minimize the assay volume and, therefore, the amounts of protein and 
nucleotide analogues.  
 
Biotek Cytation™ 3 plate-reader-based FRET assay (performed by Dr. Yi Zhao). The 
pre-mixed protein solution containing a 1:1 mixture of F-α:T-α (in equal 
concentrations and in equal volumes) was diluted with AB to a final protein 
concentration of 0.8 µM (for ClADP, FlUDP and FlUTP) or 0.4 µM (for ClATP). 100 
µL of the diluted solution was aliquoted into an individual well of a Costar 96 half-
area black opaque plate. 2 µL of each inhibitor stock solution (50x of various indicated 
concentrations) was added to a designated well. The 96-well plate was then placed 
into the Biotek Cytation™ 3 plate-reader, which was programmed with the following 
settings: shaking speed, 410 rpm; shaking time, 20 minutes (for ClADP, FlUDP and 
FlUTP) or 35 minutes (for ClATP); delay time, 5 seconds. Fluorescence intensities 
were measured using green filters: excitation, 485 ± 10 nm; emission, 528 ± 10 nm; 
top, 510 nm (optics position); gain, 35. Three replicates of these experiments were 
performed independently. By fitting the normalized fluorescence intensities and the 
inhibitor concentrations to equation 3.2 (Eq. 3.2), EC50 values of nucleotide-induced 
hRNR-α oligomerization were derived using Prism 6.0.  
 
                                                           (Eq. 3.2) 
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 In this equation, y and x represent the normalized fluorescence intensity and 
the inhibitor concentration in log-scale, respectively. 
 
Gel filtration analysis (SEC) 
 
For Figure 3-25. The typical reaction mixture in a 150 µL final volume contained 5 
mM DTT, 15 mM MgCl2, 10 µM hRNR-α and 250 µM inhibitor (ClADP, ClATP, 
FlUDP and FlUTP) or 500 µM FlUTP in 50 mM Hepes (pH 7.6).  The AM was 
incubated at 37 °C for 3 minutes prior to a 30-second centrifugation at 10,000×g at 
RT. The mixture was filtered using 0.22 µm Millex-GV syringe filter unit (Merck 
Millipore). 130 µL of the resultant filtrate was injected into a Superdex™ 200 10/300 
GL column (24 mL, 10×300 mm, GE Healthcare), attached to a Prominence HPLC 
with a photodiode array (PDA) detector (SPD-M20A) (Shimadzu Corporation), which 
had been pre-equilibrated at RT at 0.5 mL/minute flow-rate of elution buffer [50 mM 
Hepes (pH 7.6), 15 mM MgCl2, 150 mM NaCl]. The protein was eluted at 0.5 
mL/minute flow-rate at RT. Protein M.W. standard curves were obtained by running 
GE Healthcare M.W. standards (thyroglobulin, ferritin, aldolase, conalbumin, and 
ovalbumin) under identical conditions at the end of each set of experiments. A280nm 
and A260nm were monitored. Additional M.W. standards: β-amylase, BSA, and alcohol 
dehydrogenase were also independently run. An additional experiment performed for 
FlUDP included 20 µM of FlUDP in the elution buffer under otherwise identical 
conditions.   
 
For Figure 3-39A and 3-39B (right panel). Figure 3-39A, 10 µM hRNR-α was 
incubated with 4 mM dATP before splitting into two fractions. 300 µM ClADP and 
assay buffer were added to the first and the second fraction, respectively. Figure 3-39B 
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(right panel), samples were directly taken from fluorescence anisotropy (FA) assays. 
These samples were prepared and analyzed using the same conditions as described 
above for Figure 3-25. Note: 130 µL of samples from Figure 3-39A and 110 µL of 
samples from 3-39B (left panel) were injected into HPLC column. 
 
EM data acquisition and rotational symmetry analysis  
(unpublished data; performed by Huma Inayat under the guidance of Professor 
Joaquin Ortega, McMaster University) 
 
 The conditions used in our EM experiments were very similar, if not identical, 
to the conditions used in the FRET assays. For example, the incubation timescale of 
hRNR-α and indicated inhibitors was chosen based on the time-dependent FRET 
assays, which indicated when the oligomerization equilibrium was effectively reached 
(Figure 3-24A). More experimental details were described below.  
 Complexes were assembled by treating 10 µM recombinant hRNR-α with 
indicated nucleotide analogues [250 µM of ClADP, ClATP, FlUDP or FlUTP, or  
100 µM ClFDP (for positive control)] in assembly buffer [50 mM Hepes (pH 7.6),  
15 mM MgCl2, and 5 mM DTT] for 2 minutes at ambient temperature. Then, sample 
was immediately diluted 100-fold with assembly buffer in the presence/absence of 
respective nucleotide analogues prior to depositing onto an EM grid fleshly coated 
with a continuous layer amorphous carbon. Grids were floated on a 5 µL drop of the 
diluted assembly reaction for 2 minutes immediately after a glow-discharge treatment 
of a 5 mA for 15 seconds. Excess of sample was blotted with filter paper and the grids 
were stained with 1% uranyl acetate for 1 minute. A JEOL 2010F electron 
microscope, operated at 200 kV at 50,000× magnification with a dose of  
~15 electrons per Å2, was used to collect images. Images were recorded on Kodak  
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SO-163 films and scanned on a Nikon Super COOLSCAN 9000 ED at 6.35 µm per 
pixel. Electron micrographs were binned 2-fold rendering images with a sampling of 
2.54 Å per pixel.  
 Particle images in the electron micrographs were picked and extracted with 
Boxer from the EMAN package.42 Averaged ~2,000 particle images were collected for 
each reaction and subjected to image analysis as described below.  
 To perform the symmetry analysis, groups of 200 particles were normalized, 
and then translationally aligned to a circularly symmetrical global average of all of the 
unaligned particle images in the group. Rotational symmetry analysis was determined 
using the spectral ratio product and Student’s t statistical tests (t-tests) as implemented 
in the Rotastat software.43 These tests were used to compare the rotational power 
spectra of particle images containing ring-shaped particles with that of background 
images of the same size.  
 To calculate the 2D averages of the ring-shaped particles with 3-fold rotational 
symmetry, particles were normalized and then rotationally and translationally aligned 
using cross-correlation-based methods as implemented in the Xmipp software 
package.44-46 The reference used for alignments was constructed using a pyramidal 
combination of a subset of the images.47 Particles with 3-fold rotational symmetry in 
this case were selected using self-organizing feature maps as implemented in the 
Xmipp software package. By using maximum-likelihood based classification 
approaches as implemented in the Xmipp software package44-46, we were allowed to 
explore the conformational variability of the ring-shaped particles observed in the 
different reactions. For all reactions, the program was run with the number of expected 
classes equal to ten.  
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Trypsin activity assay in the presence and absence of nucleotide inhibitors 
 
 First, N-alpha-CBZ-arginine 7-amino-4-methylcoumarin hydrochloride (z-Arg-
AMC) was used to determine the trypsin activity (Scheme 3-2). Given that the product 
of this protease cleavage is a fluorescence compound AMC, we can easily detect an 
amount of AMC produced, which refers to trypsin activity, by using a fluorescence 
plate reader.  
 
 
 
 
 
 
 
 
Scheme 3-2. Trypsin cleavage of z-Arg-AMC generates a fluorescence compound, 
AMC. 
 
Standard curve of AMC (i.e., increase in fluorescence intensity as a function of AMC 
concentration). The AM in a 100 µL final volume contained 15 mM MgCl2 and AMC 
at designated concentrations (as shown in Figure 3-18A) in 50 mM Hepes (pH 7.6). 
The fluorescence intensities were recorded using a Biotek Cytation™ 3 plate-reader 
(λex = 380 nm and λem = 460 nm). The data were fit to a linear regression equation 
(Figure 3-18A).  
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Km measurement of z-Arg-AMC for trypsin.  The assay mixture in a final volume of 
100 µL contained 10 nM trypsin (or 50 mM Hepes (pH 7.6) for background), 15 mM 
MgCl2, and z-Arg-AMC at the indicated concentrations (as shown in Figure 3-18B) in 
50 mM Hepes (pH 7.6). Fluorescence intensities were recorded over 17 minutes using 
a Biotek Cytation™ 3 plate-reader (λex = 380 nm and λem = 460 nm). The rates of 
AMC production from the hydrolysis of z-Arg-AMC at the indicated concentrations 
were calculated using the linear regression equation obtained from the AMC standard 
curve (Figure 3-18A). The data were then fit to the Michaelis-Menten equation (Eq. 
3.3) to yield Km ~ 84 ± 15 µM (Figure 3-18B).  
                                    
                              (Eq. 3.3) 
 
 
 In this equation, Vmax represents the maximum enzyme velocity in the same 
unit as y while Km, the Michaelis-Menten constant, represents the substrate 
concentration needed to get a half-maximum enzyme velocity.  
 From these experiments, the activity of trypsin was affirmed. However, to 
ensure that the nucleotide inhibitors neither unexpectedly inhibit the trypsin activity 
nor quench the AMC fluorescence intensity, the following set of experiments was 
performed.  
 
Trypsin activity in the presence of nucleotide inhibitors. The assay mixture in a final 
volume of 100 µL contained 10 nM trypsin, 15 mM MgCl2, 110 µM z-Arg-AMC (~Km 
value derived from Figure 3-18B), and nucleotide inhibitors at the concentrations at 
least 10-fold above Ki (Table 3-2) [ClFDP, 3 µM; ClADP, 14 µM; ClATP, 5 µM; 
FlUDP, 94 µM; FlUTP, 68 µM; or 50 mM Hepes (pH 7.6) for control] in 50 mM 
Hepes (pH 7.6). Fluorescence intensities were recorded over 10 minutes using a 
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Biotek Cytation™ 3 plate-reader (λex = 380 nm and λem = 460 nm). The rates of AMC 
production from z-Arg-AMC hydrolysis in the absence or presence of each nucleotide 
inhibitor were calculated using the linear regression equation obtained from the AMC 
standard curve (Figure 3-18A). Each resultant trypsin activity was normalized by the 
trypsin activity obtained from the control experiment (Figure 3-18C).  
 
Percentage of fluorescence quenching of AMC by nucleotide inhibitors. The assay 
mixture in a final volume of 100 µL contained 0.25 µM AMC, 15 mM MgCl2, and 
nucleotide inhibitors [ClFDP, 3 µM; ClADP, 14 µM; ClATP, 5 µM; FlUDP, 94 µM; 
FlUTP, 68 µM; or 50 mM Hepes (pH 7.6) for control] in 50 mM Hepes (pH 7.6). 
Fluorescence intensities were recorded over 17 minutes using a Biotek Cytation™ 3 
plate-reader (λex = 380 nm and λem = 460 nm) (Figure 3-18D). 
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Figure 3-18. Trypsin activity and AMC fluorescence intensity are unaffected by 
nucleotide inhibitors. A) AMC standard curve.  B) Determination of Km of trypsin for 
z-Arg-AMC substrate by measuring fluorescence intensity of AMC formation, Km ~ 
84 ± 15 µM. C) Relative protease activity of 10 nM trypsin in hydrolysizing 110 µM 
z-Arg-AMC substrate in the presence of indicated inhibitors [ClFDP, 3 µM; ClADP, 
14 µM; ClATP, 5 µM; FlUDP, 94 µM; or FlUTP, 68 µM]. D) Each nucleotide 
inhibitor showed no significant quenching of AMC fluorescence intensity. Error bars 
designate standard error from independent duplicates.  
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 Figure 3-18C and 3-18D respectively confirmed the lack of trypsin inhibition 
and non-specific AMC-fluorophore quenching by nucleotides.  
 
Trypsin digestion analysis of 1) hexamers induced by different nucleotide inhibitors 
and 2) hRNR-α in the presence of natural nucleotides. The AM in a final volume of 
103 µL contained 3 µM hRNR-α, 15 mM MgCl2, 0.5 mM DTT, 1 µM trypsin, and 
nucleotide inhibitors [ClFDP, 3 µM; ClADP, 14 µM; ClATP, 5 µM; FlUDP, 94 µM; 
or FlUTP, 68 µM] (Figure 3-29) or natural nucleotides at the concentrations at least 
10-fold above reported Kd’s48,49 [dTTP, 18 µM; dGTP, 44 µM; dATP, 700 µM; or 
ATP, 3mM] (Figure 3-30) or buffer as control, in 50 mM Hepes (pH 7.6). The mixture 
without trypsin was pre-warmed at 37 °C for 3 minutes prior to an addition of trypsin 
to initiate the cleavage reaction. 18 µL aliquots were removed at 1, 5, 20 and 60 
minute time points and immediately quenched with 10 µL of 4x Laemmli dye 
containing 8.4% BME. To deactivate the protease activity, the mixture was 
subsequently boiled at 100 °C for 10 minutes. The relative rates of trypsin digestion of 
hexamers induced by different nucleotide inhibitors were evaluated by standard SDS-
PAGE analysis.  
 
Recovery of ClADP subsequent to enzyme inhibition  
 
 The IM in a 200 µL final volume contained 25 µM hRNR-α, 25 µM hRNR-β,  
5 mM DTT, 2.5 mM ATP, 15 mM MgCl2, 0.5 mM CDP, and 25 µM ClADP in 50 
mM Hepes (pH 7.6). For control experiment, hRNR-α and hRNR-β were replaced by 
ddH2O. The IM was incubated at 37 °C for 10 minutes. To denature the enzymes, the 
sample was subsequently boiled at 100 °C for 2 minutes prior to centrifugation at 
10,000×g for 30 seconds at RT. After the supernatant was collected, the remaining 
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residues were rinsed with 50 µL ddH2O, followed by centrifugation at 10,000×g for  
30 seconds at RT. The rinsing process was done twice. The combined supernatant was 
added to an ultracentrifugation device (YM-30 minicon) and spun at 6,000×g for  
10 minutes at 4 °C. The flow-through was collected and the YM-30 minicon was 
topped up with additional 400 µL of ddH2O before the ultracentrifugation was 
continued. This process was repeated for a total of five cycles. After removing the 
solvent of the combined flow-through using lyophilizer, the dry residue was 
redissolved in 130 µL ddH2O, filtered with 0.22 µm Millex-GV syringe filter unit, and 
100 µL of the final solution was injected onto the Ultra IBD (150×4.6 mm) column 
(Restek), which had been pre-equilibrated with 1% MeOH in buffer A [20 mM 
NH4OAc (pH 5.8)] at 1 mL.min-1 flow rate. The nucleotides were eluted isocratically 
with 1% MeOH in buffer A for 5 minutes, followed by linear gradients to 3% and 30% 
MeOH in buffer A over 25 minutes and 15 minutes, respectively. The percentage of 
MeOH in buffer A was brought up to 60% in the next 5 minutes and the last linear 
gradient to 100% MeOH was applied over 15 minutes. The diagnostic peak of ClADP 
appeared at ~21 minute retention time and the amounts of ClADP averaged over two 
runs were quantified using the known extinction coefficient (ε265: 15,700 M-1.cm-1) 
against control experiments that were run under identical conditions.  
 
Regain of hRNR-α reductase activity post dilution (estimation of off-rates) 
 
 To approximate the off-rates, the inhibited enzyme was rapidly diluted in 
dilution buffer to promote inhibitor dissociation. A regain of hRNR-α activity was 
subsequently measured as a function of time. The experimental details pertinent to 
each inhibitor are described below.  
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ClADP. The IM in a final volume of 20 µL contained 15 µM hRNR-α, 37.5 µM 
hRNR-β, 3 mM ATP, 15 mM MgCl2, 5 mM DTT and 30 µM ClADP (or ddH2O for 
control) in 50 mM Hepes (pH 7.6). The IM without the inhibitor was pre-warmed at 
37 °C for 2 minutes before ClADP (or ddH2O) was added. After incubation at 37 °C 
for another 2 minutes, the IM was diluted by an addition of 2,380 µL of pre-warmed 
buffer containing 15 mM MgCl2, 5 mM DTT in 50 mM Hepes (pH 7.6). At this step, 
the IM was diluted 120 folds. 50 µL aliquots were removed from the diluted mixture 
at indicated time points, and subsequently mixed with 5 µL of 11x stock of AM to 
precede another 1.1-fold dilution. The 11x stock of AM was prepared in a 65 µL final 
volume containing 33 µM hRNR-β, 33 mM ATP, 15 mM MgCl2, 11 mM NADPH,  
1.1 mM Trx, 11 µM TrxR, and 5.5 mM [5-3H]-CDP in 50 mM Hepes (pH 7.6). The 
individual aliquots of 11x AM stock were pre-warmed at 37 °C for 2 minutes prior to 
mixing with the respective aliquots of the diluted IM at each indicated time point.  
dCDP production was assayed over 9 minutes for each time point, followed by 
quenching with 30 µL of 2% (v/v) HClO4. Standard neutralization, dephosphorylation, 
subsequent purification and scintillation counting procedure ensued (Figure 3-33A).  
 
ClATP. The IM in a final volume of 15 µL contained 16.5 µM hRNR-α, 20 µM 
hRNR-β, 3 mM ATP, 15 mM MgCl2, 5 mM DTT and 16.5 µM ClATP (or ddH2O for 
control) in 50 mM Hepes (pH 7.6). The IM without the inhibitor was pre-warmed at 
37 °C for 2 minutes at which point ClATP (or ddH2O) was added. After incubation at 
37 °C for another 2 minutes, the IM was diluted by an addition of 2,235 µL of pre-
warmed buffer containing 15 mM MgCl2, 5 mM DTT in 50 mM Hepes (pH 7.6). At 
this step, the IM was diluted 150 folds. 150 µL aliquots were removed from the diluted 
mixture at indicated time points, and subsequently mixed with 15 µL of 11x stock of 
AM to precede another 1.1-fold dilution. The 11x stock of AM was prepared in a  
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195 µL final volume otherwise identical conditions as described under ClADP. To 
analyze the amount of [5-3H]-dC produced at each time point, the remaining steps 
listed above were followed (Figure 3-33B). 
  
FlUDP and FlUTP. The IM in a final volume of 30 µL contained 2 µM hRNR-α,  
5 µM hRNR-β, 3 mM ATP, 15 mM MgCl2, 5 mM DTT and 90 µM FlUDP or FlUTP 
(or ddH2O for control) in 50 mM Hepes (pH 7.6). The IM without the inhibitor was 
pre-warmed at 37 °C for 2 minutes at which point inhibitor (FlUDP or FlUTP) or 
ddH2O was added. After incubation at 37 °C for another 2 minutes, the IM was diluted 
by an addition of 870 µL of pre-warmed buffer containing 15 mM MgCl2, 5 mM DTT 
in 50 mM Hepes (pH 7.6). At this step, the IM was diluted 30 folds. 50 µL aliquots 
were then removed from the diluted mixture at indicated time points, and subsequently 
mixed with 5 µL of 11x stock of AM to precede another 1.1-fold dilution. The 11x 
stock of AM was prepared in a 65 µL final volume otherwise identical conditions as 
described under ClADP. The above-mentioned procedure was followed until the 
amount of [5-3H]-dC produced at each time point was analyzed (Figure 3-33C and 3-
33D). 
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Fluorescence Anisotropy (FA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-19. Fluorescence anisotropy (FA) as a tool to study molecular interactions. 
This figure is adapted from Ref. 50. 
 
 FA has been widely used for the study of molecular interactions in solution, 
i.e., protein-DNA, DNA-DNA, carbohydrate-protein, and protein-protein interactions 
etc.50,51 Figure 3-19 illustrates the principle of how FA is employed in the 
measurement of binding reactions. In solution, small molecules rotate and tumble 
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faster than larger molecules. When fluorescence-labeled small molecules in solution 
are excited with a plane-polarized light, they will tend to scramble the polarization of 
the incident light by radiating at a different direction (Figure 3-19, top), leading to the 
depolarization. However, when these fast-moving fluorescence-labeled small 
molecules bound to their interacting partners that have a large molecular mass, the 
movements of these complexes are restricted and become slower. These complexes 
will diminish the scrambling effect, and thus increase the polarization of the emitted 
light (Figure 3-19, bottom).50  
 Due to its known binding site specificity to RNR-α (S- and A-sites) and its 
commercial availability, Texas Red-5-dATP (or T*-dATP) was used as a 
fluorescence-labeled small molecule in these assays. We initially tried to study the 
binding of T*-dATP to the truncated N-terminal domain (NTD) of hRNR-α (H-NTD 
hereafter), in which only the A-site is available, and how this binding is affected by 
the ligands under study. If ClADP and FlUDP bind to the C-site, we would anticipate 
to observe an increase in FA upon treating the complex of H-NTD and T*-dATP with 
these inhibitors. However, it is also possible that the change in FA is too small until 
negligible since the M.W. of these inhibitors are relatively small compared to the 
M.W. of the protein. Thus, the difference between M.W. of protein-T*-dATP and of 
protein-T*-dATP-ligand complexes might be infinitesimal. Regardless, a drop in FA 
should not ever be expected under this assumption. Unfortunately, the sensitivity of 
the assays under these conditions was immensely low, which made the assays 
impractical. For instance, to observe a significant change in FA in a positive control, 
large amounts of H-NTD (100 µM) and dATP (8 mM) were required (data not 
shown). We, thus, replaced the H-NTD with either the wild-type hRNR-α or the 
D57N-α mutant and pre-blocked the S-site with an S-site exclusive binder, dTTP 
(Figure 3-34A).  Under these conditions, T*-dATP can only bind to the A-site. Thus, 
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if an inhibitor binds to the A-site, an excessive amount of the corresponding inhibitor 
will compete over T*-dATP, leading to a release of T*-dATP to solution. The free-
rotating/tumbling T*-dATP will consequently depolarize the incident plane-polarized 
light, leading to a drop in FA (Figure 3-19 (bottom) and 3-20). On the other hand, a 
slightly increase or no changes in FA would be expected if the inhibitor binds to the 
C-site.  
 
 
 
 
 
 
 
 
 
 
Figure 3-20. Fluorescence anisotropy (FA) assay principle. A direct binding of a 
fluorescence-labeled small molecule (fast tumbling) to its interacting partner will lead 
to a formation of a bigger fluorescence-labeled complex (slow tumbling). However, in 
the presence of an excessive amount of ligands, which specifically bind to the 
interacting partner, the fluorescence-labeled small molecule will be released to 
solution and freely rotate/tumble (fast tumbling). A drop of FA from slow tumbling 
state to fast tumbling state is then used as a readout for protein-ligand interactions.  
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Fluorescence anisotropy assays of T*-dATP with either the wild-type hRNR-α or the 
D57N-α. The AM in a 150 µL final volume contained either the wild-type hRNR-α or 
D57N-α (6 µM), T*-dATP (12 µM), KCl (100 mM), MgCl2 (15 mM), DTT (5 mM), 
5% glycerol and nucleotides of interest (dTTP, dATP, dGTP, ClADP or ClATP at 94, 
700, 250, 75 and 31 µM, respectively, or assay buffer as control) (Figure 3-36A and  
3-38) in Tris-HCl (50 mM) (pH = 7.6). The concentration of each nucleotide was 
judged by titration studies described below. The assay mixture was prepared by 
incubating T*-dATP with either hRNR-α or D57N-α for one minute before adding the 
nucleotide of interest at the indicated concentration, or assay buffer (for control). For 
the analysis of potential non-specific binding of T*-dATP (Figure 3-36C and 3-36E), 
the order of addition of T*-dATP or 700 µM dATP to the assay is designated on the  
x-axis of each plot. The mixture was thoroughly mixed and incubated for another 
minute. FA was then analyzed using a fluorescence spectrophotometer (Varian Cary 
Eclipse) (λex = 580 nm, λem = 620 nm) and equation 3.4.52-54  
 
               (Eq. 3.4) 
 
 In this equation, r and G represent fluorescence anisotropy and the correction 
factor (G-factor), respectively. Iij represents fluorescence intensity obtained after 
adjusting the polarization excitation and emission filters in i- and j-directions  
(h, horizontal or v, vertical), respectively.  
 
 For Figure 3-38A and 3-39B (left panel), the mixture without T*-dATP was 
pre-incubated for one minute with a saturating amount of the S-site exclusive binding 
nucleotide, dTTP, to pre-block the S-site or assay buffer (control). T*-dATP was then 
added to the mixture, which was subsequently mixed thoroughly. The nucleotide 
  107 
inhibitor (ClADP or ClATP at indicated concentration) or assay buffer (control) was 
added prior to another minute incubation at RT. FA was measured as mentioned 
above. Thereafter, 110 µL of both samples from Figure 3-39B (left panel), hRNR-α 
and T*-dATP in the presence of dTTP alone, or in the presence of both dTTP and 
ClADP, was directly injected into the HPLC. This procedure further validated the 
resultant oligomeric state of hRNR-α subsequent to the FA measurements (Figure  
3-39B, right panel).  
 For titration studies (Figure 3-36B, 3-36D and 3-37), the mixture without any 
nucleotides (dTTP, dATP, dGTP and ClATP) was pre-incubated with T*-dATP for 
one minute. Then, nucleotide of interest at indicated final concentrations; dTTP  
(3.5, 10.4, 31.3, 94 and 282 µM), dATP (87.5, 175, 350, 700 µM and 1.4 mM), dGTP 
(9.3, 27.8, 83.3, 250 and 750 µM) or ClATP (2, 4, 8, 16 and 31 µM) was added to the 
assay mixture. After incubating the mixture for another minute, the measurements 
were made as above.  
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3.3 Results and discussion 
 
3.3.1 Determination of active phosphorylated forms of ClA and FlU in hRNR 
inhibition   
 
 hRNR inhibition was assessed by measuring CDP reduction after incubation 
the enzyme with di- and triphosphate forms of ClA and FlU for 3 minutes (Figure  
3-21). As shown in Figure 3-22, a vast majority of the enzyme activity was inhibited 
after 3-minute incubation at 37 °C. However, there was no significantly further drop 
of enzyme activity observed when the incubation time increased. These results 
confirmed that hRNR-α activity was almost completely inhibited within 5-minute 
timescale. 
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Figure 3-21. Dose-dependent of A) ClADP, B) ClATP, C) FlUDP, and D) FlUTP for 
hRNR-α-specific CDP/ATP reductase activity (assay duration: 3 minutes).  
 
  From Figure 3-21, hRNR activity was mostly inhibited by 50 μM of 
ClAD(T)P, or 250 μM of FlUD(T)P. By fitting these data to the tight-binding equation 
(Eq. 3.1)39, an apparent Ki of each nucleotide analogue was derived and reported in 
Table 3-2. 
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Figure 3-22. Time-dependent inhibition assay of hRNR-α-specific activity in the 
presence of ClADP (5 µM), ClATP (5 µM), FlUDP (50 µM) and FlUTP (12.5 µM).  
    
Table 3-2. Inhibition constants of hRNR-α nucleotide–based inhibitors.  
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 All four nucleotide analogues [ClADP, ClATP, FlUDP and FlUTP] showed 
inhibitory effects on hRNR activity with their Ki values ranging from 0.5–10 µM. 
These results confirmed that both di- and triphosphate forms of ClA and FlU were 
active forms in hRNR inhibition. However, the binding affinities of these nucleotide 
analogues are not as good as of ClFDP and ClFTP (Table 3-2).16 
 In order to verify that hRNR inhibition induced by these nucleotide analogues 
is hRNR-α-subunit specific, we needed to prove that hRNR-β activity remains intact 
upon drug treatment. 
 
3.3.2 Time-dependent inhibition assays for hRNR-β subunit  
 
 In the IM containing 1:1 hRNR-α:hRNR-β (2 µM), MgATP, DTT, and  the 
designated inhibitor (6 µM) in 50 mM Hepes (pH 7.6), the hRNR activity was 
inhibited by ~50–70% (in the case of nucleotide analogues) or ~100% (in the case of 
3-AP). By removing aliquots from the IM at the indicated time points and immediately 
diluting into the AM, which contained excess hRNR-α, a recovery of the hRNR 
activity is expected if hRNR-β-specific activity remains unaffected. On the other hand, 
hRNR activity would remain inhibited if the inhibitor specifically affects hRNR-β-
subunit activity. 
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Figure 3-23.  Effects of ClADP, ClATP, FlUDP, FlUTP and 3-AP on hRNR-β-
subunit-specific activity. Normalized β-specific activity of 1.0 corresponds to the 
count of [5-3H]-dC generated at zero time point.  
    
  While hRNR-β-specific activity remained unchanged in the case of 3-AP, the 
known RNR-β-subunit specific inhibitor, it was recovered in the case of ClADP, 
ClATP, FlUDP and FlUTP. These data suggested that both di- and triphosphate forms 
of ClA and FlU were the active hRNR-α-specific inhibitors.  A decrease of the 
normalized β-specific activity over time, observed in Figure 3-23, was due to the 
known time-dependent intrinsic decay of diferric-tyrosyl radical cofactor-bearing 
mammalian RNR-β subunit.34 
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3.3.3 hRNR-α inhibition induced by ClA- and FlU-nucleotide analogues is 
coupled to α-subunit oligomerization  
 
 As mentioned in chapter 2 that F2CDP and di- and triphosphate forms of ClF 
inhibit RNR activity via different mechanisms.6,16,55 Here, we would like to identify 
the mechanism that ClA- and FlU-nucleotide analogues used to inhibit hRNR activity.  
 The RNR catalytic mechanism for NDP reduction at the C-site of RNR-α 
subunit is conserved from E. coli to H. sapiens.6 The only active form of F2C in RNR 
inhibition, F2CDP, hijacks this conserved catalytic pathway from RNR α2β2 
holocomplex and irreversibly inactivates the enzyme activity. This mode of inhibition 
has been observed in both bacteria and eukaryotes. F2CTP, on the other hand, has no 
effects on either α2β2 holocomplex activity or RNR-α oligomeric state.56 In contrast to 
F2C, both di- and triphosphate forms of ClF are active RNR inhibitors. They inhibited 
eukaryotic RNR by inducing RNR-α-subunit hexamerization independent of RNR-β-
subunit. Since both di- and triphosphate forms of ClA and FlU are active hRNR 
inhibitors and they specifically target hRNR-α subunit, we hypothesized that hRNR 
inhibition induced by ClAD(T)P and FlUD(T)P is directly linked to changes in hRNR-
α oligomeric states. In order to test our hypothesis, two independent methods were 
used. We firstly made use of our in-house developed fluorescence resonance energy 
transfer (FRET) reporter platform to directly report on ligand-induced hRNR-α 
oligomerization.27 Second, a formation of hRNR-α-hexamer was confirmed by using 
gel filtration analysis [Size Exclusion Chromatography (SEC)]. 
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Figure 3-24. Biotek Cytation™ 3 plate-reader-based FRET assay performed by Dr. Yi 
Zhao. A) Time-dependent analysis of the extent of fluorescence quenching in the 
FRET assay. B–C) Dose-dependent analysis of hRNR-α-subunit-specific 
oligomerization induced by B) ClAD(T)P and C) FlUD(T)P.  
 
 In the time-dependent analysis (Figure 3-24A), the assay mixture contained 1:1 
final concentrations of F-α:T-α in the presence of saturating amount of indicated 
inhibitors. The figure shows that hRNR-α oligomerization was complete induced 
within 5 minutes by ClADP, FlUDP and FlUTP or within 40 minutes by ClATP. In 
the case of ClADP, FlUDP and FlUTP, interestingly, this enzyme oligomerization 
timescale was similar to the enzyme inhibition timescale. EC50 values of inhibitor-
induced hRNR-α-subunit-specific oligomerization derived from Figure 3-24B and 
Figure 3-24C were shown in Table 3-3. Even though these EC50 values fell into the 
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same range as their corresponding Ki values previously obtained (Table 3-2), they 
cannot necessarily be directly compared due to the differences in their assay settings. 
However, given that both Ki’s and EC50’s of FlUDP and FlUTP were higher than those 
of ClA nucleotides, these data suggested that inhibition potencies are positively 
correlated to the abilities of the inhibitors to induce hRNR-α-subunit oligomerization. 
Thus, the inhibition is likely coupled with hRNR-α oligomerization.  
 
Table 3-3. EC50 values of hRNR-α nucleotide–induced oligomerization.  
 
 
 
 
 
 
 
 
 
 
 
  
 In order to confirm that these inhibitors can induce hRNR-α hexamerization, 
we measured the molecular weights of each nucleotide-induced hRNR-α oligomer 
using size exclusion chromatography (SEC).  
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Figure 3-25. Representative gel filtration chromatograms. A) M.W. standard curve 
(M.W., retention time): thyroglobulin (669 kDa, 17.6 minute); ferritin (440 kDa,  
20.6 minute); aldolase (158 kDa, 24.6 minute); conalbumin (75 kDa, 27.8 minute); 
ovalbumin (44 kDa, 29.8 minute). Additional M.W. standards: β-amylase (200 kDa, 
23.8 minute); alcohol dehydrogenase (150 kDa, 25.7 minute); and BSA (66 kDa,  
28.0 minute), were also shown.  B) hRNR-α alone. C–F) hRNR-α treated with  
C) 250 µM ClADP; D) 250 µM ClATP; E) 250 µM of FlUDP when running buffer 
contained 20 µM FlUDP (trace labeled R), or no nucleotides (trace labeled T);  
F) 250 µM (blue) or 500 µM (red) of FlUTP. 
 
 Figure 3-25, B−D, showed that the persistent hRNR-α-hexamer was observed 
after incubating the enzyme with saturating amount of ClADP or ClATP at 37 °C for  
3 minutes. Same hRNR-α-hexamer peak as well observed in the case of FlUTP. But, 
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in order to fully induce hRNR-α-hexamerization, 500 µM FlUTP was required (Figure 
3-25F). Unexpectedly, upon treating the enzyme with saturating amount of FlUDP 
with no FlUDP in the running buffer, the nucleotide was insufficient to induce hRNR-
α-hexamer. Only hRNR-α-monomer was eluted out of the column (Figure 3-25E,  
trace T). But, once 20 µM FlUDP was added into the running buffer, exclusively 
hRNR-α6 was observed (Figure 3-25E, trace R). The capability of all four nucleotide 
analogues in inducing the hRNR-α-hexamerization expanded the generality of the 
novel ligand-driven hexamerization beyond the sole example, ClF.16,56,57 However, 
given the dissimilar behavior of FlUDP-induced hexamer, it is surprising that the 
binding affinity of FlUDP to the enzyme is not significantly different from its 
analogue, FlUTP (Figure 3-21 (C−D), 3-24C, Table 3-2 and 3-3). Since ClFD(T)P-
induced hexamers are kinetically stable beyond complete inhibition dissociation57, 
whereas FlUDP-induced hexamer are unexpectedly low kinetically stable, this can be 
inferred that different nucleotide analogues induce different forms of hRNR-α-
hexamers.  
 In collaboration with Huma Inayat and Professor Joaquin Ortega from 
McMaster University, Canada, we were able to further characterize the nucleotide-
induced hRNR-α-hexamers using electron microscopy (EM) analysis.  
 
3.3.4 Conformational heterogeneity within the hexamers induced by different 
nucleotide inhibitors 
 
 To simplify the experimental setup, we initially chose not to include excess 
nucleotide inhibitors in the dilution buffer. ClFDP, which is a known hRNR-α6 
inducer16, was used as a positive control. Its electron micrograph (Figure 3-26A) 
showed ring-shaped structures, which were not observed in the control sample (Figure 
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3-26B). These results replicated Aye and coworkers’ previous work.57 ClAD(T)P and 
FlUD(T)P also showed similar electron micrographs with abundant ring-shaped 
particles (Figure 3-26, C–F (left panels)). All of these data are consistent with our 
previous SEC analysis. However, there is one worth mentioning difference in the case 
of FlUDP-induced hRNR-α6 from both techniques. FlUDP was required in the SEC 
running buffer to maintain hRNR-α6 stability while hRNR-α6 was stable in the EM 
dilution buffer with no excess FlUDP. The differences in conditions and timescale of 
the EM and SEC analyses might play a role in these different outcomes.  
 In order to identify the symmetry of the observed rings, particles from the 
electron micrographs were selected, extracted, and their rotational symmetry was 
analyzed using statistic tests (t-test and the spectral ratio product43 that pool the 
rotational power spectra of all particles in each of the samples tested). Results from 
these two tests are listed in Table 3-4.  
 In all cases, the ring-shaped particles exhibited both 3-fold and 6-fold 
rotational symmetries. We additionally observed 9-fold and 4-fold rotational 
symmetries with statistical significance in the case of the samples treated with ClATP 
and FlUDP, respectively. Because EM samples were prepared under similar 
conditions to FRET experiments, i.e., reaction timescale and final protein 
concentrations, the EM samples were believed to be in the near-complete 
oligomerization state. We, thus, rationally interpreted the observed differences in 
rotational symmetries as differences in conformational flexibility among the hexamers 
induced by different inhibitors. In most cases, particles with 3-fold rotational 
symmetry showed the highest statistical significances, indicating that the particles with 
the trimer-of-dimers architecture were more abundant than those exhibiting 6-fold 
rotational symmetry. The ring radius of the 3-fold and 6-fold rotational symmetries 
were detected at ~50 Å and ~80 Å, respectively (Table 3-4).  
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Figure 3-26. EM analysis of ring-shaped particles observed upon the treatments of 
hRNR-α with A) ClFDP (positive control), B) buffer alone (negative control), C−D) 
ClAD(T)P, or E−F) FlUD(T)P. Assembly reactions were immediately applied to the 
grid after performing a 100-fold dilution in buffer containing no inhibitor (left panels) 
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or 250 µM corresponding inhibitor (right panels). Samples were stained with 1% 
uranyl acetate and the images were taken using a transmission electron microscope 
(TEM). Insets in each panel show the 2D averages of the ring-shaped particles 
exhibiting 3-fold rotational symmetry induced by each inhibitor. Arrowheads indicate 
pleomorphic particles of different sizes accompanying the ring-shaped particles. Data 
collection and analyses in this figure were performed by Huma Inayat under the 
guidance of Professor Joaquin Ortega. 
 
Table 3-4. Rotational symmetry analysis of ring-shaped hRNR-α particles induced by 
nucleotide analogues, and subsequently diluted with the dilution buffer containing no 
inhibitors. Data collection and analyses were performed by Huma Inayat under the 
guidance of Professor Joaquin Ortega. 
 
 
 
 
 
 
 
 
 
 
 
 
 
* These p-values indicate the confidence of the symmetry determined 
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 We also prepared EM samples under different conditions in which the 100-fold 
dilution was made into buffer containing saturating amount of respective nucleotide 
inhibitors (250 µM, or at least ~27-fold above the highest Ki (Table 3-2)).  The aim of 
these experiments was to ensure that the distribution of hexameric states observed in 
Figure 3-26 (left panels) was not related to residence times of the different drugs. 
Interestingly, the efficiency of the assembly for the ring-shaped particles was reduced 
when the assembly reaction was 100-fold diluted with nucleotide-containing dilution 
buffer before applying the sample to the EM grids (Figure 3-26, right panels). The 
resulting electron micrographs showed pleomorphic particles of different sizes that 
accompany the ring-shaped particles (Figure 3-26, right panels, arrow heads). This led 
to a conclusion that the efficiency of hRNR-α to oligomerize into ring-shaped particles 
is lower in the buffer containing excess amount of nucleotide inhibitors. However, 
rotational symmetry analysis of these samples gave similar outcomes to what we 
previously observed from the samples prepared in the dilution buffer containing no 
inhibitors (Table 3-4 and 3-5).  
 Considering these two data sets together, it did not seem that the multiple types 
of rotational symmetries were simply due to the hexameric particles dissociating after 
the 100-fold dilution into the buffer containing no corresponding inhibitor; nor were 
they metastable states trapped along the hexamerization assembly pathway. Instead, 
they more likely represented end points of conformationally distinct hexamers with 
discrete rotational symmetries.  
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Table 3-5. Rotational symmetry analysis of ring-shaped hRNR-α particles induced by 
nucleotide analogues, and subsequently diluted with the dilution buffer containing 
saturating amount of respective inhibitor. Data collection and analyses were 
performed by Huma Inayat under the guidance of Professor Joaquin Ortega. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* These p-values indicate the confidence of the symmetry determined 
 
 Interestingly, a higher proportion of particles exhibiting 4-fold rotational 
symmetry was detected in the samples prepared in the dilution buffer containing 
excess amount of inhibitors. This suggested that the ring-shaped particles displayed a 
larger degree of conformational flexibility under these conditions. Up to now, the 
reason why excess inhibitors in the dilution buffer resulted in this phenotype remains 
unclear.  
 We further characterized the drug-induced particles by selecting particle 
images from both conditions, with or without inhibitors in the dilution buffer, and 
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subjecting them to a correlation averaging to obtain two-dimensional (2D) averages. 
The projection structures of particles with 3-fold rotational symmetry, the most 
abundant particles, were first obtained. To this end, self-organizing featured maps 
were used to select for particles with 3-fold rotational symmetry. Subsequently, 2D 
averages were generated. For each inhibitor, a 2D average from the samples that were 
diluted in the buffer containing either no inhibitors or 250 µM of respective inhibitor 
was acquired (Figure 3-26 insets). These averages were similar across all of the four 
nucleotide inhibitors regardless of whether the dilution buffer containing respective 
inhibitor or not. These 2D averages revealed that the ClAD(T)P and FlUD(T)P 
induced trimer-of-dimers assemblies can be viewed as three straight rods measuring 
each ~100 Å in length (Figure 3-26 insets). Rods were connected with each other 
through their ends constructing a close structure with clear 3-fold symmetry. The three 
contact points between the rods displayed a clear globular density that defined the 
three vertices of a triangle.  
 Unfortunately, there was no crystal structure of mammalian RNR-α6 
complexes available by the time we obtained our projection structures. However, 
given that hRNR-α and ScRNR-α have a 66% sequence identity, it might be 
reasonable to compare our projection structures with the previously established 6.6 Å 
crystal structure of dATP-bound S. Cerevisiae (Sc)RNR-α6 complexes.58 The crystal 
packing of the dATP-bound ScRNR-α6 can accommodate two possible hexameric 
assembly motifs, models A and B (Figure 3-27). Results from site-directed 
mutagenesis studies revealed that hexamers in solution most likely exhibited model 
B.58 In order to determine the extent to which the ring-shaped particles of hRNR-α 
induced by ClA and FlU nucleotides structurally resembled, a 2D projection of each 
model, A and B, was generated along the rotational symmetry axis. The resulting 
projections were subsequently compared to the average of the experimental 
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projections obtained by TEM. Interestingly, the 2D projection obtained from model B 
was noticeably similar to the TEM average obtained from the 3-fold symmetry-
preserving ClAD(T)P/FlUD(T)P-induced ring-shaped particles of hRNR-α. These 
results suggested that the newly characterized nucleotide-induced hRNR-α oligomers 
in their most abundant 3-fold symmetry (Figure 3-26, C−F) indeed adopt a trimer-of 
dimers architecture and the subunit arrangement was proposed as a solution model of 
ScRNR-α6 (Figure 3-27, model B). 
 In 2016, Ando et al41 successfully crystalized dATP-induced hRNR-α6 at low 
resolution (9.01 Å). The obtained crystal structure is remarkably similar to the 
hexamer model B of ScRNR-α6 (Figure 3-27, A and D). Even though a 2D projection 
of this hRNR-α6 complex has not yet been generated, it looks promising that the 
hRNR-α-subunit arrangement in this case follows the pattern of what previously 
observed in model B of ScRNR-α6 and our EM experimental projections (Figure 3-27, 
B−C). 
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Figure 3-27. hRNR-α hexamers exhibit a trimer-of-dimers architecture. A) Hexamer 
models A and B show the ribbon representations, taken from Ref. 58, of the two 
hexameric layouts observed in the 6.6 Å crystal structure of ScRNR-α. The N-
terminal domains within each ScRNR-α are shown in red. B) The corresponding 2D 
projections from each of the X-ray models A and B were generated along the 
rotational symmetry axis. The resolution of these projections was limited to 20 Å. C) 
The EM experimental projections of the hRNR-α ring-shaped particles obtained from 
ClATP treatment. D) The ribbon representation of dATP-induced hRNR-α6 taken 
from Ref. 41. The N-terminal domains within each hRNR-α are shown in green. Data 
analyses in B−C) were performed by Huma Inayat under the guidance of Professor 
Joaquin Ortega. 
 
 Additionally, the conformational variability of the inhibitor-induced ring-
shaped particles was examined using maximum-likelihood based classification 
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approaches47 (Figure 3-28). The analysis was performed for both conditions of the 
dilution buffers, with and without respective inhibitor. In each data set, all particles 
were presented in the same orientation, i.e., with the rotational symmetry axis 
perpendicular to the grid. Thus, the variation shown in the class averages is likely due 
to the existence of various conformations. Interestingly, homogenous populations of 
the ring-shaped particles were observed in the samples treated with the two 
triphosphates, ClATP (Figure 3-28C, left panel) and FlUTP (Figure 3-28E, left panel). 
The ten sub-populations obtained during the classification in each case of these two 
nucleoside triphosphates were structurally very similar, especially in the samples 
diluted in the dilution buffer containing no inhibitors. On the other hand, samples 
treated with the nucleoside diphosphates, ClADP (Figure 3-28B, left panel), FlUDP 
(Figure 3-28D, left panel), and the previously characterized ClFDP (Figure 3-28A) 
revealed ring-shaped particles with a much more obvious conformational variability. 
Some of the class averages significantly diverged from the class average obtained 
from the 3-fold symmetric particles. These differences further support the distinct 
conformational states of hRNR ring-shaped hexamers induced by the di- and 
triphosphate nucleosides. Some class averages obtained from the four inhibitors 
approximated the shape of a regular hexagon, or even a square in the case of FlUDP 
(Figure 3-28D, right panel). This last result was also consistent with the finding of the 
ring-shaped particles exhibiting 6-fold and 4-fold rotational symmetry from our 
previous rotational analysis (Table 3-4 and 3-5). It is also worth mentioning that the 
class averages acquired for the assembled rings obtained from the samples diluted in 
the buffer containing excess inhibitors (Figure 3-28, right panels) were more divergent 
compared to the another (Figure 3-28, left panels). Since the time-dependent FRET 
assay data (Figure 3-24A) suggested that all five inhibitors brought about a near-
complete hRNR-α-subunit hexamerization under these conditions, we thus proposed 
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these populations of distinct conformations represent more likely the end points, 
instead of the intermediates, of the hexamer association.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-28. Conformational variability of the hRNR-α ring-shaped particles, e.g., ✪ 
vs. v, induced by different nucleotide inhibitors; A) ClFDP, B) ClADP, C) ClATP, 
D) FlUDP, and E) FlUTP. In each case, a data set of ~2,000 particle images was 
subjected to a maximum likelihood classification approach47, assuming the existence 
of ten classes. Data collection and analyses were performed by Huma Inayat under 
the guidance of Professor Joaquin Ortega. 
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3.3.5 Trypsin digestion assays confirmed conformationally distinct hexamers 
 
 To further validate conformational differences among each nucleotide-induced 
hRNR-α hexamers, we examined the extent to which individual hexamers are sensitive 
to protease cleavage. In this assay, we chose trypsin, a serine protease that cleaves 
peptide chain mainly at the carboxylic site of arginine or lysine59, as our protease. We 
hypothesized that trypsin will cleave conformationally distinct hexamers with different 
rates, and/or generate different molecular weight fragments.  
 We found that the rates of trypsin cleavage were different among persistent 
hRNR-α-hexamers induced by the non-natural nucleotide inhibitors (Figure 3-29). 
Given that trypsin activity was unperturbed by these inhibitors under the same 
conditions (Figure 3-18C), the different rates observed must be directly due to 
conformationally distinct hexamers. Based on the comparable Ki values of FlUDP and 
FlUTP (Table 3-2), we initially expected these two nucleotide-induced hexamers were 
sensitive to trypsin to the same extent. Surprisingly, clear differences in trypsin 
cleavage rates were observed in FlUDP- and FlUTP-induced hRNR-α-hexamers 
(Figure 3-29). This finding, therefore, suggested that the differences in the observed 
trypsin cleavage rates were not associated with affinities or Ki values of the drugs. Or, 
in other words, this observation is not depending on hRNR-α structure stabilization 
caused by ligand binding. 
 In contrast to results from Figure 3-29, hRNR-α in the presence of natural 
nucleotides showed no appreciable sensitivity to the trypsin protease (Figure 3-30). 
Interestingly, the enzyme sensitivity was not also observed when hRNR-α was treated 
with dATP, a known RNR-α-hexamer inducer. This observation further supports the 
intrinsic differences between RNR-α hexameric states induced by dATP and other 
non-natural nucleotide inhibitors.55  
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Figure 3-29. hRNR-α hexamers induced by different nucleotide inhibitors were 
cleaved by trypsin at different rates.  A) SDS-PAGE analysis of the samples in which 
hRNR-α was pre-treated with buffer (“No drug”) or indicated drugs prior to the 
addition of buffer containing no trypsin (−) or 1 mg.mL-1 trypsin protease (+). M, 
M.W. marker. B–C) Relative hRNR-α (92 kDa, monomer) and ~60 kDa band 
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intensities of indicated drug-treated samples, respectively. To obtain the relative 
values, the designated band intensity of each drug-treated sample was compared to 
that of “No drug” sample of any particular gel.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-30. hRNR-α in the presence of natural nucleotides (dTTP, dGTP, dATP, and 
ATP) was resistant to trypsin. hRNR-α was pre-treated with buffer (“No drug”) or 
natural nucleotides prior to the addition of buffer containing no trypsin (−) or 1 
mg.mL-1 trypsin protease (+). M, M.W. marker. 
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3.3.6 ClADP and FlUDP exhibit reversible mode of hRNR-α-specific inhibition  
 
 ClADP and FlUDP are anticipated to bind to the catalytic site (C-site) on the α-
subunit as previously demonstrated for ClFDP16 and F2CDP6. Similar to F2CDP and 
many other inactivators6,55, the binding of ClADP and FlUDP to the C-site could 
possibly engage in a chemical reaction with the transient thiyl radical generated during 
the RNR catalytic cycle (Figure 3-31). Alternatively, like ClFDP16, they could bind to 
the C-site without being chemically modified. 
 
 
 
 
 
 
PCET, Proton-Coupled Electron Transfer. 
 
Figure 3-31.  The paradigm of irreversible RNR inactivation by F2CDP and other 
nucleotide analogues.6,55  
 
 In order to identify the mode of hRNR-α-specific inhibition by ClADP and 
FlUDP, we examined to what extent ClADP and FlUDP could be recovered post 
enzyme inhibition. A molar equivalent of ClADP was added to an assay mixture 
containing 1:1 hRNR-α and hRNR-β under turnover conditions to initiate enzyme 
inhibition. After heat-inactivation, denatured enzymes were removed, and small-
molecule fraction was analyzed by HPLC (Figure 3-32).  
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Figure 3-32. ClADP was recovered quantitatively post enzyme inhibition. A) HPLC 
diode array traces of nucleotide and other assay small-molecules extracted from 
inhibition mixture. Inset shows a comparison of ClADP peaks, of which retention time 
is ~21 minute, observed between the extracts from inhibition mixture (red) or control 
mixture (no enzymes, otherwise identical conditions) (blue).  B−C) UV-visible 
absorbance spectra corresponding to the peak maxima at 21-minute retention time of 
the red (   ) and blue (−) HPLC traces, respectively. In both cases, λmax shows at  
265 nm. 
  
 If ClADP irreversibly bound to hRNR-α, we would not have been able to 
recover ClADP from this experiment since it would have been stuck to the enzyme 
and removed from the assay mixture prior to the injection into HPLC. From our two 
independent replicates, however, we found greater than 98% of ClADP was recovered 
(Figure 3-32A), which indicated the reversibility of hRNR-α inhibition induced by 
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ClADP. After trying the analogous experiment with FlUDP, unfortunately, FlUDP 
was not stable under the HPLC elution conditions.   
 To validate whether FlUDP reversibly induces hRNR-α inhibition, we 
measured the off-rate of FlUDP dissociation by monitoring a recovery of hRNR-α 
CDP-reductase activity upon dilution. The measurements were also extended to 
include FlUTP, ClADP, and ClATP. A time-dependent regain of hRNR-α activity was 
observed for each of the four inhibitors subsequent to dilution, and the half-lives of 
dissociation were all around 1–2 minutes (Figure 3-33).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-33. The time-dependent regain of hRNR-α-subunit-specific activity 
subsequent to dilution-assisted dissociations of A) ClADP B) ClATP C) FlUDP and 
D) FlUTP. Percentage activities were derived based on the results from control 
experiment where the inhibitor was replaced by assay buffer.  
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 Based on the experimental conditions employed for inhibition and dilution, and 
the derived Ki values (Figure 3-21, Table 3-2), theoretical percentages of the inhibitor-
bound form (EI) formation and the EI dissociation subsequent to dilution of each 
drug-treated sample were calculated and shown in Table 3-6.  
 
Table 3-6. Theoretical percentages of the EI formation and the EI dissociation from 
each drug-treated sample. The percentages were calculated based on the estimated 
apparent Ki’s of the inhibitors (Table 3-2) and the final concentrations of hRNR-α and 
respective inhibitors in the pre- or post-dilution samples. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 The theoretical percentages shown in Table 3-6 represent the incompletion in 
EI formation and EI dissociation of each drug-treated sample under these 
conditions. Unfortunately, we were not able to increase the fold dilution due to low 
assay sensitivity and intrinsically low activity and stability of the mammalian enzyme. 
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These experimental limitations prevented us to achieve a full hRNR-α-specific activity 
regain (Figure 3-33). Nevertheless, we were able to observe a time-dependent regain 
of hRNR-α activity for each of the four inhibitors upon dilution. This affirms that 
these four nucleotide inhibitors reversibly inhibit hRNR-α-specific activity.  
 Because the hexamers induced by ClF nucleotides persist beyond inhibitor 
dissociation in the absence of other competitor nucleotides57, these half-life values 
likely reflect off-rates of the inhibitor ligands rather than intrinsic stability of the 
hexamers. Since the ligand-off rate is 5–10-fold shorter than the retention time of 
hexameric state observed in gel filtration analysis (Figure 3-25), these data further 
support that the stability of different hexamers on gel filtration does not reflect 
different ligand residence times, but instead inherently different hRNR-α6 states.  
 Thus far, we have shown that these four nucleotide analogues reversibly inhibit 
hRNR-α-specific activity by inducing distinct hRNR-α hexamers. We, next, 
investigated at which binding site(s) of the α-subunit that each inhibitor binds to.  
 
3.3.7 Determination of binding site specificities of each nucleotide inhibitor 
 
 Based on the basis of the enzymatic activity of hRNR as an NDP reductase, 
binding of triphosphate nucleosides to the C-site is not possible. However, the  
α-subunit possesses two triphosphate-binding allosteric sites, S- and A-sites (Figure  
3-34). We hence initially expected ClATP and FlUTP to bind to either the S- or the A-
site, and the diphosphates of ClA and FlU to bind to the C-site at the α-subunit.  
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PCET, Proton-Coupled Electron Transfer; NTD, N-terminal Domain. 
 
Figure 3-34. A) Human α2β2 holocomplex and natural nucleotides that bind to specific 
site(s) at the α-subunit. B) Schematic representation of the two domains, NTD and 
catalytic body, of hRNR-α.  
 
 To verify whether or not these inhibitors bind to the A-site, we first unitized 
the previously characterized D57N-human RNR-α (D57N-α) mutant. A loss of the 
ability of the wild-type hRNR-α to discriminate between ATP and dATP at the A-site 
in this D57N point mutation is known.48,58 For instance, D57N-α fails to hexamerize 
when treated with dATP under physiological conditions, only D57N-α-dimer is 
observed. Contrarily, it could still form hexamer when treated with ATP.58 Due to the 
A-site defectiveness of D57N-α (Figure 3-34B), any A-site binding nucleotides hence 
assumed to no longer inhibit D57N-α activity. Under this assumption, the A-site 
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binding specificity of ClFTP was verified in 2011 by Aye and Stubbe.16 We then 
examined the D57N-α-inhibiting ability of the four nucleotide inhibitors.  
 Under conditions where wild-typed hRNR-α was fully inhibited, the D57N-α 
point mutant was unresponsive to all four inhibitors at the final concentrations at least 
10-fold above the measured Ki’s for the wild-type (Figure 3-35). Since the binding of 
ClATP and FlUTP to the C-site is not possible as mentioned above, these data indicate 
that the triphosphates of ClA and FlU promote hRNR-α inhibition via the A-site 
binding, similar to ClFTP.16 In the case of diphosphates of ClA and FlU, these 
observations were opposed to our expectations. Since the C-site of this mutant is 
known in literatures16,60 and shown by our experimental results (Figure 3-8) to fully 
function, we expected to see the D57N-α inhibition upon the treatments of ClADP and 
FlUDP. Based on these unanticipated data (Figure 3-35, C–D), more information to 
inevitably identify the binding site specificity of these diphosphate inhibitors was 
needed. Nevertheless, these results are still striking for two reasons. First, it confirms 
that both ClADP and FlUDP are not mechanism-based inactivators, since the well-
established mechanism-based inactivator, gemcitabine diphosphate (F2CDP), 
efficiently inhibits both D57N-α and the wild-type. Second, because the D57N-α is 
unable to adopt the deactivated α-hexameric state(s)58,60, these data are consistent with 
our hypothesis that hexamerization is a prerequisite for RNR inhibition. In contrast to 
our results, the recently identified α6-inducer ClFDP can inhibit D57N-α activity.16 
These differences likely reflect nuanced binding modes for the different ligands. In 
order to understand this phenomenon, further analyses beyond the scope of this project 
are required.  
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Figure 3-35. The recombinant D57N-α mutant remained largely uninhibited by A) 
ClATP, B) FlUTP, C) ClADP, and D) FlUDP under the conditions in which wild-type 
hRNR-α was inhibited (Figure 3-21). Percentage activities were calculated based on 
the results from control experiment where the inhibitor was replaced with assay buffer. 
The concentration ranges were identical to those known to sufficiently inhibit the 
wild-type hRNR-α (Figure 3-21, Table 3-2).  
  
 Next, we designed assays that combine fluorescence anisotropy (FA) and gel 
filtration analyses to further investigate the binding site specificity of ClADP and 
FlUDP. Because the lower Ki’s of ClADP compared to FlUDP and of ClATP 
compared to FlUTP (Table 3-2), ClADP and ClATP were used as representative 
examples of FlUDP and FlUTP, respectively. We first introduced the wild-type 
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hRNR-α to a solution of free T*-dATP, which resulted in a significant increase in FA 
(Figure 3-36A). This result was consistent with the formation of a protein-ligand 
complex (Figure 3-20). Under these conditions in which there is no competing ligands, 
T*-dATP can independently bind to both S- and A-sites. Exclusive binding of 
nucleotide effectors to the S-site induces RNR-α dimerization. Regardless of S-site 
occupancy, A-site binding causes RNR-α hexamerization.61 We next examined 
whether or not there is a nonspecific binding of T*-dATP to the enzymes (both wild-
type and D57N-α mutant). A titration of non-labeled dATP to a solution of 6 µM of 
wild-type hRNR-α or D57N-α mutant and 1.2 µM of T*-dATP revealed that 700 µM 
dATP was sufficient to saturate both enzymes (Figure 3-36, B and D, the 4th bar from 
the left).  However, not all of the labeled T*-dATP was displaced upon an addition of 
700 µM dATP into a solution of hRNR-α and T*-dATP or D57N-α and T*-dATP. The 
same results were obtained even though the order of addition of T*-dATP and dATP 
was swapped (Figure 3-36, C and E). Even though this finding indicated the 
nonspecific binding of T*-dATP to the enzymes, it should not affect our assay 
interpretation because, in these experiments, only specific release of the dye from 
specific sites upon the addition of a competitive ligand matters.  
 Based on the inhibition assays of D57N-α, ClATP was shown to bind to the A-
site at the α-subunit. We, thus, used ClATP to verify this FA assay reliability. First, 
saturating amount of dTTP (Figure 3-37A), an exclusive S-site binder, was introduced 
to a solution of hRNR-α treated with T*-dATP, in which an equilibrium of S- and A-
site-bound forms was reached. We observed a 49 ± 1% drop in FA, which must 
represent a replacement of the S-site binding T*-dATP by the non-labeled dTTP 
because the S-site and the A-site are not coupled (Figure 3-38A). There is also a 
possibility of the compensatory binding of the displaced T*-dATP to the A-site. 
Subsequent addition of ClATP in a saturating amount (Figure 3-37C) to this mixture 
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resulted in a further 20 ± 1% decrease in FA (Figure 3-38A). The simplest explanation 
of these results is due to ClATP displacing some of the bound T*-dATP at the A-site. 
These outcomes not only added a further credence that ClATP binds to the A-site, but 
also validated the FA assay reliability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-36. Fluorescence anisotropy (FA) studies with T*-dATP. The concentrations 
of T*-dATP and protein (hRNR-α or D57N-α) were kept consistent at 1.2 and 6 µM, 
respectively. A) Representative increase in FA upon addition of wild-type hRNR-α to 
a solution of T*-dATP. Since absolute values of FA fluctuate between different 
experiments, this measurement needs to be performed each time that the FA assays are 
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set up. However, a relative drop in FA is consistent for a given protein and ligand(s). 
B–E) The confirmation of nonspecific binding of T*-dATP to wild-type hRNR-α (B–
C) or mutant (D–E). The saturating amount of dATP used in C) and E), 700 µM, was 
judged by the titration results in B) and D), respectively. The lowest concentration of 
dATP used was 87.5 µM and the concentration was doubled up to 1.4 mM. By 
comparing FA values from the systems in which the protein was sequentially 
incubated with T*-dATP and 700 µM dATP in a different order of addition, the 
existence of nonspecific binding of T*-dATP to these proteins was confirmed (C and 
E). Error bars designate SD (n=3). Inset shows the binding site specificities of the 
three natural nucleotide ligands used in these FA studies. The experimental data in this 
figure are interpreted on the assumption that T*-dATP binds to the same site as dATP. 
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Figure 3-37. Titration studies of nucleotides into a solution of T*-dATP and wild-type 
hRNR-α or D57N-α. The concentrations of T*-dATP and protein (hRNR-α or D57N-
α) were kept consistent at 1.2 and 6 µM, respectively. Five concentrations of each 
nucleotide were used (dTTP: 3.5, 10.4, 31.3, 94 and 282 µM; ClATP: 2, 4, 8, 16 and 
31 µM; dGTP: 9.3, 27.8, 83.3, 250 and 750 µM).  In C), T*-dATP was added to 
hRNR-α, of which the S-site was pre-blocked with suturing amount of dTTP (94 µM, 
Figure 3-37A). Then, ClATP was added to the mixture prior to FA measurement. 
Error bars designate SD (n=3). The experimental data in this figure are interpreted on 
the assumption that T*-dATP binds to the same site as dATP. 
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Figure 3-38. Determination of ClATP binding site specificity by fluorescence 
anisotropy (FA). The concentrations of T*-dATP, protein (hRNR-α or D57N-α), 
ClATP, dTTP, dGTP were 1.2, 6, 31, 94, and 250 µM, respectively.  A) Addition of 
ClATP to a solution containing hRNR-α, T*-dATP (S- and A-site binder) and dTTP 
(S-site exclusive binder) resulted in a decrease in FA, suggesting ClATP binds to the 
A-site at the α-subunit. B) Addition of ClATP to a sample containing the defective-A-
site-binding D57N-α mutant and T*-dATP, which exclusively binds to the S-site of 
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the mutant, led to a small decrease in FA compared to the values obtained when the S-
site exclusive binders (dTTP or dGTP) were added. C) When wild-type hRNR-α was 
used in place of the mutant, T*-dATP can bind to both S- and A-sites. Thus, upon 
ClATP addition, a higher drop in FA compared to that shown in B) was observed. 
Error bars designate SD (n=3). The experimental data in this figure are interpreted on 
the assumption that T*-dATP binds to the same site as dATP. 
 
 In another set of experiments, we made use of both wild-type hRNR-α and 
D57N-α mutant. First, 6 µM of the A-site-defective D57N-α mutant was incubated 
with 1.2 µM T*-dATP. Since the A-site is not available in this mutant, the binding of 
T*-dATP was thus exclusive to the S-site. By adding a saturating amount of dTTP (94 
µM, Figure 3-37B), we observed a 39 ± 1% drop in FA (Figure 3-38B). A same level 
of percentage drop in FA was observed when an alternative S-site-only binder, dGTP, 
was used in placed of dTTP.   In contrast, the addition of ClATP gave a ~7-fold less 
decrease in FA compared to that observed in dTTP or dGTP (Figure 3-38B). Second, 
when these experiments were repeated with wild-type hRNR-α, ClATP gave rise to a 
significantly higher drop in FA (Figure 3-38C). This data set further confirmed the A-
site-binding specificity of ClATP. Although the allosteric regulation of RNR is 
complicated, the FA data (Figure 3-38) together with the D57N-α inhibition analysis 
(Figure 3-35, A–B) are strongly consistent with the triphosphates of ClA and FlU bind 
to the A-site. 
 Next, we performed two independent sets of experiments to demonstrate that 
ClADP, a representative example of the diphosphate inhibitors, does indeed associate 
with the C-site. In the first set of experiments, wild-type hRNR-α was incubated with 
saturating amount of dATP (for both S- and A-sites) such that only the C-site was 
available for any newly added ligands. Under these conditions, hRNR-α adopts 
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hexameric states. After splitting the sample into two equal portions, ClADP and assay 
buffer were separately added to the first and second portions, namely sample A and B, 
respectively. Each sample was injected into a gel filtration column, which had been 
pre-equilibrated with running buffer containing no inhibitors, and the oligomeric state 
of eluted hRNR-α was evaluated. A hexameric peak was observed only in sample A 
(Figure 3-39A, magenta trace). Our gel filtration result in this study with ClADP 
(Figure 3-25C) showed that hRNR-α pre-treated with ClADP maintained its 
hexameric state, a remarkable feature of kinetic stability that unique to the drug-
induced hexamers, even when there was no ClADP in the running buffer. Gel filtration 
results in previous studies with dATP from us16 and others3, on the other hand, have 
shown that in the absence of excess dATP in the running buffer, RNR-α pre-treated 
with excess dATP only elutes as low-order species. Thus, in the present experiment, 
the observation of any hexameric peaks in the gel filtration profile from sample A (and 
not in the control sample B) could only be a result from the interaction of ClADP with 
the C-site of hRNR-α, generating the observed kinetically stable hexamers.  
 In the second set of experiments, FA measurements were coupled with gel 
filtration analysis. Wild-type hRNR-α (6 µM) was incubated with T*-dATP (1.2 µM), 
and the S-site was subsequently blocked by dTTP in saturating amount (94 µM, Figure 
3-37A). We first showed the similar decrease in FA (~50%, Figure 3-39B, left panel) 
compared to the change obtained in Figure 3-38A (right panel). Then, the sample 
mixture was either treated with the suturing amount of ClADP (75 µM) or assay buffer 
(for control). The addition of ClADP caused no statistically significant changes in FA 
(Figure 3-39B, left panel), unlike the addition of ClATP, which resulted in ~20% 
further drop in FA due to T*-dATP displacement (Figure 3-38A, right panel). These 
results suggested that ClADP interacts with neither S- nor A-sites. When these 
samples were separately analyzed by gel filtration analysis, the sample treated with 
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ClADP resulted in an appreciable fraction of hexamers, whereas the control sample 
eluted exclusively as a monomer (Figure 3-39B, right panel). Thus, T*-dATP and 
ClADP must occupy hRNR-α simultaneously under the conditions where ClADP site 
occupancy is appreciable, thereby leading to a significant proportion of α-hexameric 
state in the elution profile. These two sets of experiments (Figure 3-39) provided 
convincing evidence that ClADP induces hRNR-α hexamerization through interaction 
with the C-site only. 
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Figure 3-39. Determination of ClADP binding site specificity using both gel filtration 
analysis and fluorescence anisotropy (FA). A) ClADP C-site-binding specificity 
determined by size exclusion chromatography (SEC). Gel filtration analysis of  
hRNR-α treated with assay buffer alone (black trace), saturating amounts of dATP 
alone (green trace, sample B), ClADP alone (blue trace), or both (magenta trace, 
sample A). α6 peak observed only when ClADP was additionally included, but not in 
the dATP-saturated sample where both S- and A-sites occupied. This suggested that 
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ClADP binds at the C-site. B) ClADP C-site-binding specificity determined by FA 
coupled with gel filtration analysis. ClADP caused no statistically significant changes 
in FA consistent with ClADP interacts with neither the S- nor A-sites (left panel). 
Upon direct injection of the sample treated with ClADP (the second bar in the plot), a 
considerable fraction of hRNR-α hexamers was observed, whereas a sole monomer 
peak was observed in the control sample (the first bar in the plot). Error bars designate 
SD (n=3). The experimental data in this figure are interpreted on the assumption that 
T*-dATP binds to the same site as dATP. 
 
Conclusions 
 
 In this chapter, we have shown that hRNR enzyme inhibition is coupled with 
α-hexamerization. This coupling is insinuated by the fact that the Ki’s for all of the 
inhibitors studied (Figure 3-21, Table 3-2) and the EC50’s of oligomerization (Figure 
3-24, Table 3-3) have similar values. This finding helps elucidate why the 
diphosphates of ClF, ClA, and FlU are not RNR mechanism-based inhibitors, because 
a binding of these diphosphates under this model requires rapid modulation of hRNR-
α to a conformation that is incapable of PCET.   
 Our inhibition assays showed that ClA and FlU nucleotides bind to hRNR-α 
with diverse affinities (Table 3-2), which fairly dispersed in a range of 0.5–10 µM. 
These nucleotides also showed comparable off-rates within minutes time-scale, which 
is 5–10-fold shorter than a time-scale of our gel filtration experiments (Figure 3-25 
and 3-33). Under the gel filtration time-scale, FlUDP eluted solely as a monomer 
unless FlUDP was also included in the running buffer. The hRNR-α-hexameric states 
from other drug-treated samples, on the other hand, did not require any inhibitor 
supplementation in the running buffer to maintain their hexameric states (Figure 3-25, 
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B–D, F and Figure 3-39, A and C). These data suggested that different nucleotide 
inhibitors induce structurally different hexamers, which were retained after ligand 
dissociation. The divergent conformations of these drug-induced hexameric states 
were further confirmed by the 2D averages of the drug-induced-ring-shaped particles 
obtained from our EM studies together with the different rates of trypsin protease 
cleavage among these hexamers (Figure 3-26, 3-28, 3-29 and 3-30). 
 The oligomerization-defective mutant, D57N-α, and fluorescence anisotropy 
(FA) were used as tools to determine binding site specificity of these nucleotide 
inhibitors. Even though the D57N-α mutant cannot hexamerized58, 60, its C-site is still 
available and active16 (Figure 3-8). As expected, ClATP and FlUTP failed to inhibit 
D57N-α under the conditions that they inhibited wild-type hRNR-α (Figure 3-35,  
A–B). This observation and the FA data (Figure 3-38) suggest that the triphosphates 
exclusively interact with the A-site. Unexpectedly, both ClADP and FlUDP, the 
enzyme-substrate analogues, failed to inhibit the mutant activity (Figure 3-35, C–D). 
This might be a result from a cross-talk between the C- and the A-sites upon a 
diphosphate-inhibitor binding. By performing FA assays coupled with gel filtration 
analysis, the C-site-binding specificity of these diphosphates was confirmed (Figure  
3-39). Based on the results from these two independent sets of experiments, we 
proposed that ClADP and FlUDP must not only bind to the substrate-binding C-site 
but also induce the α-hexameric state.  
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 CHAPTER 4 
 
In Cell Studies of Cladribine and Fludarabine 
 
4.1 Introduction 
 
 Cladribine (ClA) and Fludarabine (FlU) are purine nucleoside analogues that 
are currently used in treatments of lymphoproliferative disorders.1 These two drugs 
were developed after the discovery of an anticancer agent, 9-β-D-arabinofuranosyl-
adenine (araA) (Figure 4-1).2-5 Nowadays, araA is no longer used in clinic due to its 
poor solubility and rapid deamination by the ubiquitous adenosine deaminase (ADA), 
which leads to a loss of its pharmacological activity.2,6 By having a halogen atom 
substituted at the C2 position of the adenosine moiety (Figure 4-1), ClA and FlU are 
resistant to the deamination by ADA.2 In 1977, years after discoveries of ClA (1972)3 
and FlU (1968)4, Carson et al7 found that activities of deoxyadenosine kinase and 
deoxyguanosine kinase, crucial enzymes for many drugs’ activation, are largely 
confined in lymphoid tissues, where ADA is present in high concentration8. They, 
therefore, proposed that an ADA-resistant deoxypurine analogue would be selectively 
toxic to lymphocytes.7 This helps explain why ClA and FlU are effective in treating 
patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.  
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Figure 4-1. Chemical structures of 9-β-D-arabinofuranosyladenine (araA), Cladribine 
(ClA) and Fludarabine (FlU). 
 
 The administered form of FlU in clinical use is fludarabine-5′-monophosphate, 
FlUMP, unlike ClA.2,9,10 The phosphate group helps improve drug solubility, however, 
it will get hydrolyzed off by plasma phosphatase and ecto-5′-nucleotidase before 
entering cells. Nucleoside transporters are known to mediate the transport of these 
purine nucleosides into cells.2  
 In this chapter, we evaluated the ability of ClA and FlU to inhibit enzyme 
ribonucleotide reductase (RNR) activity in cells as well as drug toxicity in cell lines 
expressing wild-type RNR-α or oligomerization-defective D57N-α under inducible 
promoter.  
   
4.2 Experimental 
 
General Materials and Methods. Antibodies to mammalian ribonucleotide reductase 
α subunit (Ab81085), mammalian ribonucleotide reductase p53β (Ab8105), 
mammalian ribonucleotide reductase β subunit (Ab57653), mouse anti-rabbit IgG 
(HRP) (Ab99702) and goat anti-mouse IgG H&L (HRP) (Ab6789) were from Abcam. 
NH4+ salt of [5-3H]-CDP (19.4 Ci/mmol) was from ViTrax. Fetal Bovine Serum (FBS) 
for cell experiments was from Sigma Aldrich. Other cell culture media, Bovine Calf 
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Serum (BCS) and Trypan Blue Stain (0.4%) were obtained from Gibco® Life 
Technologies. AlamarBlue® dye for cell viability assay was from Thermo Fisher 
Scientific. 96-well tissue culture plates with 0.33 cm2 cell growth area and 60 mm×15 
mm cell culture dishes were purchased from CELLTREAT® and Corning, 
respectively. Number of cells was counted by using Countess® II FL automated cell 
counter from Thermo Fisher Scientific. Cell viability assays were measured using 
Cytation™ 3 from BioTek®. Curve fitting and data analyses were performed using 
Prism v7.0 (Graphpad).  
 
NIH-3T3 cell culture protocol  
 
 NIH-3T3 cells stably expressed with either wild-type or D57N mouse RNR-α 
(mRNR-α), generated by Dr. Minxing Li11, were cultured at 37 °C under 5% CO2 
atmosphere. DMEM supplemented with 10% BCS, 100 µg/mL streptomycin sulfate, 
and 100 U/mL penicillin was used as media. Both cell lines were maintained and 
passaged in the presence of 1.25 µg/mL puromycin and the puromycin containing 
media were changed every two days. Cell passages were performed when the cells 
reached ~80% confluence by rinsing with 1x DPBS, followed by trypsinization, and 
centrifugation at 800×g at RT for 8 minutes.  
 
Drugs treatment in cells 
 
 In a 150-mm tissue culture media dish (CELLTREAT®), either wild-type 
mRNR-α or D57N mRNR-α overexpressing 3T3 monolayer cultures at 80–100% 
confluence were treated with either DMSO (vehicle), Clofarabine (ClF), ClA, or 
FlUMP at indicated concentrations and incubated at 37 °C under 5% CO2 atmosphere 
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for 3 hours. Cells originating from two 150-mm plates at 80–100% confluence were 
used for each set of radioactive assays for cell lysate. After cell harvesting, each pallet 
was subsequently lysed according to previously published protocols.12,13 The resulting 
lysate was immediately used in radioactive assays for cell lysate. 
 
Radioactive assays for cell lysate 
 
 Typical assay mixture (AM) of CDP reduction in a final volume of 135 µL 
contained 3 mM ATP, 10 mM DTT, 0.5 mM [5-3H]-CDP (Specific activity (SA) = 
25,000 cpm/nmol), and the lysate mentioned in Drugs treatment in cells in assay 
buffer (AB) [50 mM Hepes (pH 7.6), 15 mM MgCl2]. The AM without [5-3H]-CDP 
was pre-warmed at 37 °C for 2 minutes prior to the substrate addition. Four 30 µL-
aliquots were removed at 40, 80, 130 and 180 second time-points post assay initiation, 
and immediately quenched with 2% (v/v) HClO4 (30 µL). The mixture was 
subsequently neutralized with 30 µL of 0.4 M NaOH. Dephosphorylation of the 
resultant [5-3H]-dCDP was achieved by adding 410 µL of dephosphorytion mixture 
containing 10 units CIP, 1.2 mM deoxycytidine (dC) in 100 mM Tris-HCl (pH 8.6) 
and incubating the mixture at 37 °C for 2 hours. Unreacted [5-3H]-CDP was removed 
by loading the resultant mixture onto a borate column, which had been prepared by 
using method of Steeper and Steuart.14 The amount of [5-3H]-dCDP formed at each 
time-point was analyzed using liquid scintillation counting.  
 
Western blot of cell lysates  
 
 Western blot analysis was carried out as previously reported.12,13 Antibodies to 
mammalian ribonucleotide reductase α subunit (Ab81085) and goat anti-mouse IgG 
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H&L (HRP) (Ab6789) were used as primary and secondary antibodies at 1:1,000 and 
1:5,000 dilutions, respectively. For loading controls, membranes were re-probed with 
mouse monoclonal anti-GAPDH-peroxidase (1:30,000 dilution) (monomer, 37 kDa) 
(Figure 4-3). For Figure 4-4A, antibodies to mammalian ribonucleotide reductase α 
subunit (Ab81085) and mouse anti-rabbit IgG (HRP) (Ab99702) were used for 
primary and secondary antibodies at 1:1,000 and 1:4,000 dilutions, respectively. In 
order to probe mammalian RNR-p53β, antibodies to mammalian RNR-p53β (Ab8105) 
at 1:2,000 dilution and mouse anti-rabbit IgG (HRP) (Ab99702) at 1:4,000 dilution 
were used for primary and secondary antibodies, respectively. Antibodies to 
mammalian ribonucleotide reductase β subunit (Ab57653) at 1:2,000 dilution and goat 
anti-mouse IgG H&L (HRP) (Ab6789) 1:4,000 dilution were used for primary and 
secondary antibodies to probe mammalian ribonucleotide reductase β subunit, 
respectively. Mouse monoclonal anti-GAPDH-peroxidase (1:2,000 dilution) was used 
for loading controls.  
 
Cell viability assays  
 
 Flp-In T-REx HEK293 cell lines expressing RNR-α- (wild-type) or D57N-α-
2×Flag were generated by Dr. Marcus J. C. Long. Flp-In T-REx HEK293 cells were 
cultured in MEM supplemented with 10% FBS, 1x pyruvate and non-essential amino 
acids, 100 µg/mL zeocin and 1x penicillin/streptomycin in a humidified atmosphere at 
37 °C with 5% CO2 atmosphere. 400,000 of the cells were seeded in 6-well plates. 
After 24 hours, plates were co-transfected with (A) 3:1 and (B) 6:1 plasmid mix 
containing the POG44 vector encoding the Flp recombinase and pcDNA5/FRT/TO-
RNR-α- or D57N-α-2×Flag (2.5 µg total plasmid) using Mirus 2020 (7.5 µL) in 6-well 
plates as per manufacturer’s instructions. Two days after transfection or when the cells 
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reached confluence, the cells were trypsinized. The two separate transfection 
conditions (A and B) were pooled and plated in 10 cm dishes. After 1–1.5 days, the 
cells were changed to selective media containing 150 µg/mL Hygromycin B. After 
1.5–2 weeks, single colonies had formed. Once the colonies were large enough to 
pick, individual clones were selected using cloning cylinders. Individual clones were 
grown in 12-well plates, and verified for expression using anti-flag western blot (+/− 
200 ng/mL tetracycline, 24 hours) and immunofluorescence (which showed cytosolic 
Flag-tagged wild-type or D57N-α upon tetracycline induction). For passaging lines 
post selection, 100 µg/mL Hygromycin B was used.  
 Flp-In T-REx HEK293 cells expressed with either wild-type or D57N RNR-α 
were seeded in 60 mm×15 mm cell culture dishes (Corning) at 37 °C under 5% CO2 
atmosphere. The media used was DMEM supplemented with 10% FBS, 100 µg/mL 
streptomycin sulfate and 100 U/mL penicillin. After cells attached to the dishes  
(1–2 days), Hygromycin B was added to a final concentration of 50 µg/mL. Cells were 
trypsinized after they reached ~80% confluence and the number of cells was counted 
using Trypan Blue Stain (Gibco® Life Technologies) and Countess® II FL automated 
cell counter (Thermo Fisher Scientific). 2,500 cells, in 100 µL media, were seeded in 
96 well plates (CELLTREAT®) without Hygromycin B. 50 µL of 300 ng/mL 
tetracycline or media alone (without tetracycline) was added into each well. Cells were 
cultured at 37 °C under 5% CO2 atmosphere for 11 hours. 50 µL of indicated drugs at 
4x of indicated concentrations or media alone (for control) were added into designated 
wells. Cells were left at 37 °C under 5% CO2 atmosphere for 45 hours before 90 µL of 
media was removed. 11 µL of alamarBlue® dye was subsequently added into each 
well. After 48 hours of drug treatment, cell viabilities were determined using 
Cytation™ 3 (BioTek®) (λex = 560 nm, λem = 590 nm). Normalized fluorescence 
intensities (y-axis) were plotted against log values of drug concentrations in molar 
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scale (x-axis). The data were fit into equation 4.1 using Prism v7.0 and EC50 values 
were derived.  
 
                 Eq. 4.1 
 
4.3 Results and discussion 
 
4.3.1 ClA and FlU inhibit wild-type mRNR-α but not the oligomerization-
defective mD57N-α in NIH-3T3 fibroblasts 
 
 Tumors are classically considered as wounds that do not heal, which implies 
that cells that are responsible in the response of injury and angiogenesis, such as 
fibroblasts and endothelial cells, have an important role in the progression, growth and 
spread of cancers.15 Also, elevated RNR expression is one of cancer-characteristics.16 
We thus chose to assess the ability of ClA and FlU to inhibit RNR in NIH-3T3 
fibroblast cells stably expressing with either wild-type or D57N mRNR-α, which were 
generated by Dr. Minxing Li. (See Ref. 11 for more details) 
 In 1981, Weinberg et al17 first identified D57N-α, a single point mutation at 
the A-site of RNR (Figure 4-2), during their studies of the effects of natural nucleotide 
pool imbalance in mouse (m) T-lymphosarcoma cells. By mutating aspartic acid (D) at 
position 57 to asparagine (N), dATP-mediated RNR enzyme inhibition is disrupted. 
Later, Reichard et al18 and Kashlan et al19 confirmed that the D57N point mutation 
renders mRNR-α resistant to dATP-driven RNR inhibition. Furthermore, in 2006, 
Rofougaran et al20 discovered that mRNR forms an inactive α6β2 octomer in the 
presence of dATP. Based on this evidence, it is most likely that the mD57N mutant is 
not inhibited by dATP due to its incapability to form α-hexamers.  Thus, if there is any 
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connection between RNR-α hexamerization and RNR inhibition promoted by ClA and 
FlU nucleotides, we expected ClA and FlU to inhibit wild-type mRNR-α but not the 
mD57N-α in NIH-3T3 fibroblasts.  
 
 
  
 
 
Figure 4-2. Schematic representation of the two domains, NTD and catalytic body, of 
mRNR-α.  
 
 We first treated NIH-3T3 cells stably expressing wild-type mRNR-α with a 
known RNR-α-hexamerization inducer, ClF13,21,22, ClA, FlUMP or DMSO (vehicle) at 
the concentrations similar to those used in previous pharmacological studies23-25 for  
3 hours.  The mRNR-α subunit-specific activity after drug treatment was evaluated by 
measuring the rate of [5-3H]-dCDP product formation in cell lysates. Similar to the 
results observed in the positive control (ClF-treated cells), lysates from ClA- and 
FlUMP-treated cells showed potent RNR inhibition (Figure 4-3, top).  
 Next, we investigated the effects of these compounds on cells stably 
expressing the oligomerization-defective point mutation D57N-α19, which we found to 
be resistant to a known RNR-α-hexamerization inducer ClFTP21 but not to the 
mechanism-based inactivator gemcitabine 5′-diphosphate (F2CDP). The in cell and in 
vitro data for the latter drug were provided by Dr. Yuan Fu (See Ref. 11 for more 
details). The CDP/ATP-reductase-activity of mRNR in NIH-3T3 expressing mD57N-
α lines was not suppressed by either ClA or FlUMP (Figure 4-3, bottom). These results 
showed an inhibition signature that involves protein hexamerization similar to the 
allosteric RNR-inhibitor, ClF.13,21 Given that the D57N-α-expressing mutant lines 
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showed resistance to ClF, whereas they were sensitive to F2C11, an important hint 
about potential links between RNR inhibition promoted by ClA/FlU nucleotides and 
α-hexamerization was provided by this set of experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. Evaluation of the ability of ClA and FlUMP to inhibit mRNR-α subunit-
specific CDP/ATP-reductase-activity from NIH-3T3 cell lysates. NIH-3T3 cells stably 
expressing either wild-type mRNR-α (top) or D57N mRNR-α (bottom) were treated 
with DMSO (vehicle), 5 µM ClF23, 50 µM ClA25 or 300 µM FlUMP24 for 3 hours 
prior to cell harvesting and lysis. The mRNR-α subunit-specific activity of 500 µg of 
total lysate was determined by immediately measuring the rate of [5-3H]-dCDP 
product formation over 4 time-points. Error bars designate SD (n=2). 
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4.3.2 RNR-α oligomerization plays a role in cytotoxic activity of ClA and FlU 
 
 We have shown in chapter 3 that ClA- and FlU-nucleotide-induced RNR 
inhibition is coupled to RNR-α-oligomerization. We next evaluated to what extent the 
oligomeric mode of RNR inhibition plays a role in drug cytotoxic profiles.  
 Flp-In HEK293 T-REx cells that can stably incorporate a single copy of a 
selectable transgene at a defined genomic locus upon transient transfection with a 
plasmid encoding flippase (FLIP) recombinase, and an appropriate donor plasmid 
containing flippase recognition target (FRT) sites were used in the following 
experiments. Even though, the toxicity of these nucleosides to normal cells versus 
cancer cells depends on various parameters, we here focused on gaining initial insights 
into the importance of oligomeric regulation in the ultimate cytotoxic activity of these 
nucleosides. The Flp-In HEK293 T-REx cells constitutively express the tetracycline 
(tet)-repressor to facilitate the tet-inducible expression of the transgene of interest. 
Isogenic lines stably expressing either RNR-α-Flag or D57N-α-Flag under a  
tet-controlled CMV-promoter were established. By using this system, we can thus 
temporally control the protein expression, which allows us to spotlight the effects from 
(wild-typed and mutant) RNR-α alone against a native background.  
 As evidenced by Flag blot, these clonogenic lines showed undetectable 
expression of ectopic RNR-α. But, upon 11-hour tet-exposure, the total RNR-α levels 
were upregulated approximately 2–3 folds relative to the endogenous protein. 
However, the levels of RNR-β and RNR-p53β, the two isoforms of RNR-β subunit, 
were unaffected under these conditions (Figure 4-4).   
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Figure 4-4. Validation of tetracycline (tet)-induced RNR-α or D57N-α overexpression 
in Flp-In T-REx HEK293 cell lines. (A) A representative western blot. Protein level 
was analyzed using indicated antibodies to RNR-α subunit and the two isoforms of 
RNR-β subunit. GAPDH was used as a loading control. Note: Since mammalian 
RNR-β is known to be labile for cleavage at the N-terminal PEST domain26, multiple 
bands always observed when an RNR-β containing protein blot is probed with anti-
RNR-β. (B) Quantification of protein fold upreguration normalized over GAPDH.  
  166 
 We next set up a proliferation inhibition assay in which cells were seeded at 
10% confluence in 96-well plates, then treated with tet for 11 hours prior to the drug 
addition. After 48 hours (approximately 2.5 doubling time) of drug treatment, total 
viable cells were measured using alamarBlue® reagent. AlamarBlue® is widely used 
as an indicator of metabolic and cellular health in cell viability bioassays.27 This dye is 
non-toxic, water-soluble, stable in culture media and permeable through cell 
membranes. The dye acts as an intermediate electron acceptor in the electron transport 
chain without any interference of the normal transfer of electrons.28 By comparing 
oxidation-reduction potentials of alamarBlue® and other electron carriers in the 
electron transport chain at 25 °C, pH 7.0 (Table 4-1), alamarBlue® can be reduced by 
NADPH, FADH, FMNH, NADH, as well as the cytochromes.27 Once the indicator 
dye accepts electrons, it changes from its non-fluorescent, blue-colored-oxidized state 
to the fluorescent, pink-colored-reduced state.28 
 
Table 4-1. Oxidation-reduction potentials in the electron transport system.27  
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 Measurements of this color change are quantitative (colorimetric and/or 
fluorometric readings). Based on our in vitro data in chapter 3, we would expect that 
overexpression of RNR-α and D57N-α would similarly protect HEK293 cells from 
gemcitabine (F2C) for three reasons. First, F2CDP (the only active form of 
gemcitabine that inhibits RNR) targets the C-site of both wild-type RNR-α and the 
reduced-affinity-A-site-binding mutant D57N-α.11 Second, as shown in Figure 4-4, 
RNR-α overexpression is similar in both lines. Third, the specific activities of D57N-α 
and wild-type RNR-α are comparable. For the RNR-α inhibitors, that inhibit the 
enzyme activity by inducing RNR-α-hexamerization, we hypothesized that over-
expression of oligomerization-defective D57N-α should rescue cell toxicity, whereas 
overexpression of wild-type RNR-α should elicit some protection in cases where the 
Ki value of the inhibitor under study is lower or not much greater than the wild-type 
RNR-α cellular concentrations. Our experimental hypothesis is shown in Figure 4-5. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5. The experimental hypothesis of cell viability assays.  
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 Over three separate runs, each with quadruplicate data, we observed modest 
protection against F2CDP cytotoxicity upon tet-induction of RNR-α or D57N-α 
relative to the noninduced samples (Figure 4-6A and 4-7). As we expected, the fold 
protections observed in RNR-α and D57N-α overexpression were not significantly 
different, and the magnitude of protection (3–5 folds, Figure 4-7) was on the order of 
the RNR-α overexpression we observed in Figure 4-4B.  
 In the case of ClF and ClA, RNR-α overexpression cells elicited a small effect 
on the EC50 value relative to the noninduced cells (Figure 4-6, B–C and 4-7), similar 
to the results with F2C. In contrast, D57N-α overexpression showed almost complete 
protection (>20 folds in each case) against both ClF and ClA treatment (Figure 4-7). 
These results were not from an unlikely scenario that the global nucleotide pool is 
being perturbed by D57N-α overexpression since RNR-α and D57N-α expressing cells 
were still sensitive to artificial nucleotide-induced toxicity. We can thus conclude that 
ClF and ClA selectively target RNR-α through oligomeric downregulation as we 
initially expected. In the case of FlUMP, no protection was observed in both RNR-α 
and D57N-α overexpression (Figure 4-6D and 4-7). By considering the higher Ki’s of 
FlUDP and FlUTP, compared to those of ClFD(T)P and ClAD(T)P, together with the 
relatively low amount of protein overexpression we observed in this system (Figure  
4-4), any rescue upon RNR-α overexpression would be unlikely. These observations 
implied that RNR-α is a low-priority target of FlU-nucleotides, whereas it is the 
principal target of ClF- and ClA-nucleotides.  
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Figure 4-6. Dose-dependent viability assays of (A) F2C, (B) ClF, (C) ClA, (D) 
FlUMP, (E) an RNR-β-specific inhibitor, Triapine (3-AP)29, and (D) an HSP90 
inhibitor, 17-AAG.30 Since neither 3-AP nor 17-AAG targets RNR-α, no protection 
was observed in either RNR-α or D57N-α overexpression.  
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Figure 4-7. Quantification of fold protection upon tet-induction of samples treated 
with F2C, ClF, ClA, or FlUMP (data from Figure 4-6).  
 
Conclusions 
 
 Chemotherapy is one of the key modes of cancer treatment. However, the 
effectiveness of nucleotide chemotherapy is limited by drug resistance.31 Conventional 
views mostly attribute mechanisms of nucleotide drug resistance to a reduction of 
intracellular concentration of drug active species and/or a suppression of apoptosis 
induction.1,31 In this chapter, we investigated the functional impacts of defective 
oligomeric regulation of RNR-α under conditions where drug uptake and metabolism, 
interaction with other targets, and apoptosis pathway induction processes are 
unaltered. Our in-cell data showed that RNR-α hexamerization is potentially an 
additional pathway to cytotoxic resistance to RNR-α6-inducer nucleotides such as 
those of ClF and ClA. This finding differentiates these nucleotides from the more 
well-characterized conventional suicide inactivators such as F2C.  
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 APPENDIX A 
 
ZRANB3: A Binding Partner of RNR α-subunit 
 
 Dr. Yuan Fu discovered a binding interaction between zinc finger Ran-binding 
domain-containing protein 3 (ZRANB3) (Figure A-1) and RNR-α subunit while 
screening a random-primed cDNA library from HeLa cells using a fusion protein 
RNR1-GAL4BD as bait; the cDNA library was constructed in pP6 vector, and RNR1-
GAL4BD constructed in pB43.  This hit clone was subsequently verified by 
immunoprecipitation (unpublished data). 
 
 
 
 
 
 
 
 
Figure A-1. Modular structure of ZRANB3.1 ZRANB3 possesses several functional 
domains, i.e., 1) a helicase core at its N-terminus is a characteristic for the SNF2 
ATPase family members, 2) a PCNA-interacting protein motif (PIP-box), 3) an 
unusual zinc finger of the NZF-type (Npl4 zinc finger)2, 4) a putative HNH-type 
endonuclease domain at the C-terminal, and 5) APIM (AlkB homologue 2 PCNA-
interacting motif)3, residues 1074–10781, which is part of the HNH domain. This 
Figure is adapted from Ref. 1. 
 
 
 To identify which domain(s) of ZRANB3 (Figure A-1) that RNR-α interacts 
with, we first examined the HNH domain, whose name derived from the three most 
conserved histidine (H) and asparagine (N) residues in the degenerate motif1.  
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 As the APIM domain is part of the HNH domain in ZRANB3 and can interact 
with PCNA (a protein that controls RNR activity during DNA synthesis)4, we 
designed two truncated proteins: (1) His6-HA-HNH and (2) His6-flag2-HNHΔAPIM, 
to investigate whether the APIM domain is necessary for interaction(s) (if any) 
between RNR-α and the HNH domain of ZRANB3.     
 
Generation of His6-HA-HNH and His6-flag2-HNHΔAPIM plasmids 
 
 HNH and HNHΔAPIM were separately amplified from the plasmid encoding 
flag-ZRANB3, a generous gift from Weston et al1, using the primers shown in Table 
A-1. The result gene was finally cloned into an empty pET28a vector. The genes were 
confirmed by sequencing at the Cornell University Life Science Core Laboratories 
Center (Figure A-2).  
 
Table A-1. Primers used for the construction of His6-HA-HNH and His6-flag2-
HNHΔAPIM.  
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Figure A-2. Amino acid sequences of A) His6-HA-HNH, and B) His6-flag2-
HNHΔAPIM. Sequences of His6-tag, HA-tag, flag2-tag, HNH, and APIM are colored 
in black, green, orange, purple, and blue, respectively.  
 
Recombinant protein expression and purification 
 
 His6-HA-HNH and His6-flag2-HNHΔAPIM proteins were expressed and 
purified as previously described for hRNR-α (chapter 3) with the following 
modifications: 450 µM and 150 µM IPTG were used to induce the expression of  
His6-HA-HNH and His6-flag2-HNHΔAPIM, respectively. The obtained cell pellet was 
lysed in lysis buffer (50 mM Tris-HCl, pH 8.0, 800 mM NaCl, 10 mM imidazole,  
5 mM BME, 1 mM PMSF, 10% glycerol and 0.2% Triton X-100). After a removal of 
DNA by adding 2% (wt/v) streptomycin sulfate, the supernatant was incubated with 
TALON® metal affinity resin, which was pre-equilibrated with 10 column volumes 
(CV) of lysis buffer, for 1 hour. The suspension was then re-loaded on the column, 
and the resin was washed with 1 bed volume (BV) (×2) of wash 1 buffer (50 mM Tris-
HCl, pH 8.0, 800 mM NaCl, 15 mM imidazole, 5 mM BME, and 0.2% Triton X-100), 
followed by 1 BV of wash 2 buffer (50 mM Tris-HCl, pH 8.0, 800 mM NaCl, 20 mM 
imidazole, 5 mM BME, and 0.2% Triton X-100). The desired protein was then eluted 
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out with elution buffer (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 125 mM imidazole, 
and 1 mM BME). The protein-containing fractions were pooled and injected into a fast 
protein liquid chromatography (FPLC), which had been pre-equilibrated with at least 5 
BV of storage buffer (30 mM Hepes, pH 7.8, 50 mM NaCl, 0.25 mM EDTA, 1 mM 
DTT, 0.01% NP40, and 10% glycerol). According to the resulting chromatogram, the 
protein-containing fractions were pooled and subsequently concentrated using 
centricons (10 kDa M.W. cut-off). Protein purity was determined using SDS-PAGE. 
 
His6-flag2-HNHΔAPIM. 
 
 
 
 
 
 
Figure A-3. A) FPLC chromatogram of His6-flag2-HNHΔAPIM with high imidazole 
concentration and B) 15% SDS-PAGE gel of purified His6-flag2-HNHΔAPIM  
(27 kDa). 
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His6-HA-HNH. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-4. A) FPLC chromatogram of His6-HA-HNH with high imidazole 
concentration and B) 15% SDS-PAGE gel of purified His6-HA-HNH (27 kDa). 
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Examination of protein interactions 
 
 Binding interactions between (1) hRNR-α and HNH, and (2) hRNR-α and 
HNHΔAPIM were preliminary tested by using gel filtration analysis [Size Exclusion 
Chromatography (SEC)]. In this study, we evaluated two oligomeric states of hRNR-
α, monomers and ClFDP-induced-hexamers (hRNR-α6). The typical reaction mixture 
in a 150 µL final volume contained 50 µM HNH (or HNHΔAPIM) protein, 10 µM 
hRNR-α, 15 mM MgCl2, 5 mM DTT, 15.5 µM ClFDP (for the ClFDP-induced-hRNR-
α6) or assay buffer (for the monomers) in 50 mM Hepes (pH 7.6). For the hRNR-α 
monomers, the reaction mixture was incubated at 37 °C for 3 minutes prior to 
filtration and injection into a column as previous described in Gel filtration analysis 
(SEC) (chapter 3). For the ClFDP-induced-hexamers, the reaction mixture without 
HNH (or HNHΔAPIM) was pre-incubated at 37 °C for 2 minutes prior to addition of 
the protein of interest and subsequent incubation at 37 °C for another 3 minutes, 
filtration, and injection onto a column; 1 mL fractions were collected and 2% from 
each fraction was used for SDS-PAGE analysis. Protein bands were visualized by 
silver staining (Figure A-5 and A-6). 
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Figure A-5. Examination of the interactions between hRNR-α (90 kDa) and 
HNHΔAPIM (27 kDa). A–B show characteristic profiles of purified recombinant 
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hRNR-α and HNHΔAPIM, respectively. C–D show profiles of the reaction mixture of 
HNHΔAPIM and two oligomeric states of hRNR-α; C) the monomers and D) the 
ClFDP-induced-hRNR-α6. Right panels show SDS-PAGE gel analyses of fractions 
obtained from the corresponding SEC chromatograms shown on the left panels. Note: 
A smear observed on the SDS-PAGE gel of the hRNR-α alone sample (★) was not 
from the recombinant protein, but most likely from a contaminant on the gel cassette.  
 
 Shown in Figure A-5A, the purified recombinant hRNR-α eluted from the 
column during 25–31 minute retention time, while the purified recombinant 
HNHΔAPIM eluted during 29–33 minutes (Figure A-5B). However, incubation of 
HNHΔAPIM with hRNR-α and subsequent SEC analysis yielded an additional band 
~90 kDa, which corresponds to hRNR-α, in fraction 11 (Figure A-5C, right panel). 
This band was not observed in the recombinant hRNR-α alone control (Figure A-5A, 
right panel). Likewise, upon incubation of HNHΔAPIM with the ClFDP-induced-
hRNR-α6, hRNR-α eluted during 19–33 minutes retention time (Figure A-5D, right 
panel). From our previous data, however, ClFDP-induced-hRNR-α6 alone in the 
absence of the HNHΔAPIM normally eluted as a single peak around 19–21 minute 
retention time (data not shown). Similar results were also observed when HNH was 
used instead of HNHΔAPIM (Figure A-6). Under an assumption that the similar 
results observed from these two independent sets of experiments are from protein-
protein interactions, the APIM domain does not seem to be an essential factor for the 
binding between the HNH domain and hRNR-α (either in monomeric or hexameric 
states). Since we cannot exclude the possibility that these two proteins just co-elute, 
further experiments (i.e., pull-down assays using specific affinity resins) are needed to 
confirm their binding interactions.    
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Figure A-6. Examination of the interactions between hRNR-α (90 kDa) and HNH  
(27 kDa). A–B show characteristic profiles of purified recombinant hRNR-α and 
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HNH, respectively. C–D show profiles of the reaction mixture of HNH and two 
oligomeric states of hRNR-α; C) the monomers and D) the ClFDP-induced-hRNR-α6. 
Right panels show SDS-PAGE gel analyses of fractions obtained from the 
corresponding SEC chromatograms shown on the left panels. Note: this set of 
experiments and the one from Figure A-5 were independently performed.  
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APPENDIX B 
 
1H and 31P NMR Spectra of ClA(M/D/T)P and FlU(D/T)P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-7. 1H-NMR spectrum of ClAMP (600 MHz, D2O).  
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Figure A-8. 31P-NMR spectrum of ClAMP (501 MHz, D2O, H3PO4 external 
reference). 
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Figure A-9. 1H-NMR spectrum of ClADP (600 MHz, D2O). 
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Figure A-10. 31P-NMR spectrum of ClADP (501 MHz, D2O, H3PO4 external 
reference). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-11. 1H-NMR spectrum of ClATP (600 MHz, D2O). 
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Figure A-12. 31P-NMR spectrum of ClATP (400 MHz, D2O, H3PO4 external 
reference). 
 
 
 
 
 
 
 
 
 
 
 
Figure A-13. 1H-NMR spectrum of FlUDP (600 MHz, D2O) 
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Figure A-14. 31P-NMR spectrum of FlUDP (501 MHz, D2O, H3PO4 external 
reference). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-15. 1H-NMR spectrum of FlUTP (600 MHz, D2O) 
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Figure A-16. 31P-NMR spectrum of FlUTP (501 MHz, D2O, H3PO4 external 
reference). 
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APPENDIX C 
 
Fluorescence Resonance Transfer (FRET) Quenching Assays  
Supporting Information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-17. Fluorescence intensities measured after adding 0.5 µL of either assay 
buffer (20 mM Hepes, pH 7.6) for a control, 22 mM ClADP, or 22 mM ClATP into 
the original assay mixture (220 µL) containing F-α and T-α in a 1:5 ratio at the 
indicated time points post incubation at RT.   (Assay final volume = 220.5 µL) Final 
concentrations were calculated under an assumption that changes in volume was 
negligible.  
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Figure A-18. Fluorescence intensities measured after directly adding 0.5 µL of either 
assay buffer (20 mM Hepes, pH 7.6) for a control, 22 mM ClADP, or 22 mM ClATP 
into the mixture obtained from Figure A-17 at the indicated time points post 
incubation at RT.   (Assay final volume = 221 µL) Final concentrations were 
calculated under an assumption that changes in volume were negligible. 
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Figure A-19. Fluorescence intensities measured after directly adding 1.5 µL of either 
assay buffer (20 mM Hepes, pH 7.6) for a control, 22 mM ClADP, or 22 mM ClATP 
into the mixture obtained from Figure A-18 at the indicated time points post 
incubation at RT.   (Assay final volume = 222.5 µL) Final concentrations were 
calculated under an assumption that changes in volume were negligible. 
 
 
 
